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Organic cation transporters (OCTs) belong to the organic cation/anion/zwitterion 
transporter family SLC22, which is part of the major facilitator superfamily. The OCT 
family contains three influx transporters, OCT1, 2, and 3, which share high sequence 
homology. OCT1-3 exhibit broad tissue distribution, including the heart, intestine, 
kidney, liver, choroid plexus, neurons and brain capillaries [1]. They play a pivotal role in 
the absorption, tissue distribution, and excretion of a diverse array of substances, 
including drugs, toxins, xenobiotics and neurotransmitters (e.g. metformin, morphine, 
	   xvii	  
serotonin) [1]. OCT substrates exhibit a wide variety of structural and physiochemical 
properties and currently the nature of the biochemical interactions between substrate 
and OCTs are unknown. Therefore, identifying which amino acid residues are critical for 
OCT-substrate interactions is of central importance to understanding and predicting 
interactions between drugs and OCTs. Our long-term goal is to identify and verify 
crucial amino acid residues for interaction at the substrate-binding pocket of human 
OCT3 (hOCT3), which will support breakthroughs in understanding drug absorption, 
clinical drug-drug interaction, and compound excretion, as well as inform rational drug 
design strategies for hOCT3 interacting drugs. The working hypothesis for this project is 
that substitution of hOCT3 residues involved in transporter-substrate interactions, 
implicated through in silico molecular modeling and docking studies, will result in altered 
affinity (Km) of the transporter to the substrate. 
A three-dimensional (3-D) homology model of human OCT3 was generated using 
the solved crystal structure of a high affinity phosphate transporter from Piriformospora 
indica (PiPT) as template. A putative binding pocket for the prototypical hOCT3 ligand 
1-methyl-4-phenylpyridinium (MPP+) was identified through docking studies and five 
residues, Phe36, Val40, Trp358, Glu451 and Asp478, were identified as potentially 
mediating hOCT3-MPP+ interactions. Next, a series of conservative and non-
conservative amino acid substitutions were introduced to these positions via site-
directed mutagenesis. Screening experiments showed that conservative substitution at 
position Trp358 or Asp478, non-conservative substitution at position Val40, as well as 
the double mutant Phe36Tyr-Glu451Ala, each resulted in complete loss of MPP+ 
transport activity by hOCT3. Kinetic analyses using generated cell lines expressing 
	   xviii	  
functional hOCT3 mutants in isolation (Phe36Ala, Phe36Tyr, Val40Leu, Glu451Ala, 
Glu451Asp, Phe36Tyr-Val40Leu and Val40Leu-Glu451Ala) provided Km values for 
MPP+ of 29.1±2.0µM, 14.6±0.5µM, 32.2±4.3µM, 40.9±4.8µM, 23.4±3.9µM, 14.4±1.7µM 
and 70.0±9.7µM, respectively. Thus, the Km values for all mutants, with the exception of 
Phe36Tyr and Phe36Tyr-Val40Leu, were significantly increased (indicating reduced 
affinity) over that of wild type hOCT3 (16.0±2.2µM). All of the residues identified through 
docking studies appear to influence MPP+-hOCT3 binding interactions, with Trp358 and 
Asp478 being the two most important residues. Additionally, 3-D homology modeling of 
the functional hOCT3 mutant Val40Leu, and all non-functional hOCT3 mutants, 
indicated changes in binding pocket architecture consistent with weakening of ligand-
transporter interactions. Docking of structurally divergent hOCT3 substrates indicated 
binding interactions in the same general region as that identified for MPP+, albeit with 
mostly unique residues, suggesting the presence of one large binding pocket with 
substrate-specific contacts. Interspecies differences were explored by generating 3-D 
homology models for rat and murine Oct3. Results from docking studies using 
compounds exhibiting vastly different binding affinities (Km or IC50) towards the 
OCT3/Oct3 orthologs were consistent with varying strength in ligand-transporter binding 
pocket interactions being the underlying driver for interspecies differences in transporter 
affinity. 
Finally, a series of novel compounds exhibiting anti-depressant-like activity was 
screened for OCT interaction in vitro. Results demonstrated significant inhibitory effects 
on OCTs for many of the compounds, with several being the most potent OCT inhibitors 
identified to date (e.g., KAI414). These data suggest that their pharmacological action 
	   xix	  
may be through inhibition of the OCT component of the uptake-2 system in the CNS. 
Based on their inhibition profiles, lead compounds (e.g., KAI414) were prioritized for 
conducting in vivo pharmacodynamic studies. Now, this series of compounds can be 
docked to our validated OCT3 3-D homology models to identify crucial functional groups 
for transporter-ligand interactions supporting further rational drug design. 
In conclusion, this dissertation research successfully generated 3-D homology 
models for human, rat and murine OCT3/Oct3. Through a series of in silico and in vitro 
studies a ligand-binding region was defined, and putative residues mediating 
transporter-ligand interactions identified and verified. Docking studies with compounds 
exhibiting interspecies differences in affinity support the conclusion that differences in 
the binding pocket architecture and strength of molecular interactions with those 
residues form the basis for inter-species differences in transporter compound affinity. 
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CHAPTER 1 
ORGANIC CATION TRANSPORTERS: IDENTIFICATION OF STRUCTURAL 
ELEMENTS IMPACTING TRANSPORTER-SUBSTRATE INTERACTIONS 
 
 
1.1 Overview of Organic Cation Transporters 
Progress has been made in understanding the role of membrane transporters in 
drug safety and efficacy [2]. In particular, more than 400 membrane transporters in two 
major families – the ATP-binding cassette (ABC) family, which directly binds and 
hydrolyzes ATP as a driving force for the unidirectional transport of substrates, and the 
solute carrier (SLC) family, which is indirectly coupled to cellular energy and utilize the 
membrane potential difference and/or the stored energy of chemical gradients as driving 
forces – have been annotated in the human genome [3]. Many of these transporters 
have been cloned, characterized, and localized to tissues and cellular membrane 
domains in the human body. The effect of transporters on drug disposition, therapeutic 
efficacy and other aspects has been demonstrated in numerous studies. Currently, the 
human SLC superfamily is comprised of over 50 separate gene families with a 
combination of more than 350 confirmed and putative transporter proteins [4]. The 
SLC22 family contains organic cation/anion/zwitterion transporters with about 30 
identified/putative members including organic cation transporters (OCTs and OCTNs), 
which may interact with hundreds of organic cations, weak bases and some neutral 
compounds [1]. 
	  	   2	  
The members of the SLC22 transporter family are all characterized by 12 α-
helical transmembrane domains (TMDs) with a pseudosymmetry between TMDs 1 – 6 
and 7 – 12, a large extracellular loop located between TMDs 1 and 2 with three 
glycosylation sites that are hypothesized to mediate homo-oligomerization and 
intracellular routing, as well as six sulfhydryl groups (conserved cysteine residues) that 
could potentially form disulfide bridges; a large intracellular loop between TMDs 6 and 
7, which is proposed to be involved in posttranscriptional regulation (through 
phosphorylation), and intracellular N- and C-termini (hypothesized structure of the 
SLC22 transporter family shown in Figure 1.1) [5, 6]. OCTs utilize electrochemical 
gradients of the transported compounds as their driving forces to uptake organic cations 
into the negatively charged intracellular environment as facilitated diffusion carriers. 
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Figure 1.1 Predicted secondary structure of SLC22 transporters [6]. 
 
  
	  	   4	  
Since the identification and characterization of the first member of the family in 
1994, other family members were cloned from species including human, mouse, and rat 
[1]. Three major OCT subtypes (OCT1, OCT2, and OCT3) have been identified; they 
share structural as well as substrate similarities. On the amino acid level, organic cation 
transporter subtypes from rat, mouse, and human exhibit cross-species identities of 78-
95% (OCT1), 81-91% (OCT2), and 87-93% (OCT3); within one species (rat, mouse, or 
human), the amino acid identities between different subtypes are 67-70% between 
OCT1 and OCT2, 47-57% between OCT1 and OCT3, and 49-51% between OCT2 and 
OCT3 [7]. Recently, focus has been turned to investigate the function of transporters in 
different organs, regulation of transporter expression, biochemical implications of the 
transporters, and to understand the transport mechanisms. 
Cloned from rat (r) liver in 1994, rOct1 (Slc22a1) was the first member of the 
SLC22 family to be identified, and was later cloned from human, mouse and rabbit [1, 
8]. OCT1 is mainly expressed in liver where it is located in the sinusoidal membrane of 
hepatocytes; strong expression is also found in kidney in rodents (rat and mouse) and 
rabbits, while only small amounts of SLC22A1 mRNA were detected in human kidney. 
Human OCT1 is expressed in various additional organs including small intestine, lung, 
heart, skeletal muscle, brain, placenta, mammary gland, adrenal gland, eye, adipose 
tissue, immune cells, and various tumors [5]. OCT1 has broad substrate specificity. 
Most substrates of human OCT1 are monovalent organic cations including model 
cations such as tetraethylammonium (TEA+), 1-methyl-4-phenylpyridinium (MPP+), 4-[4-
(dimthylamino)-styryl]-N-methylpyridinium (ASP), and 4’,6-diamidino-2-phenylindol 
(DAPI); endogenous compounds including salsolinol, polyamine putrescine; and 
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therapeutics such as the antidiabetic drug metformin, antiviral drugs, antiparasitic drugs, 
and so on [5]. OCT1 mediates the uptake of substrates across the sinusoidal membrane 
into hepatocytes, which is the first step in hepatic excretion of many substances; and 
the transporter also facilitates passage of endogenous substrates and drugs across the 
blood-brain barrier (BBB). Inter-individual differences in expression of OCT1, which may 
be influenced by genetic and epigenetic factors, cause differences in hepatic excretion 
and tissue distribution of drugs such as metformin. To date, at least 23 coding single 
nucleotide polymorphisms (cSNPs) have been identified for human OCT1 [9]. Three of 
these SNPs (Arg61Cys, Cys88Arg, and Gly401Ser) resulted in decreased uptake of 
MPP+, indicating that they might be involved with hOCT1-MPP+ interaction [10]. Twelve 
of these SNPs have been shown to affect functionality of hOCT1 towards metformin by 
in vitro and in vivo data, thus these SNPs might be responsible for the variability 
observed in patients (Table 1.1) [11, 12]. 
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Table 1.1 Summary of OCTs non-synonymous SNPs associated with metformin disposition. 
 
   Functional Effect  
 dbSNP ID Mutation In vitro In vivo References 
SLC22A1 
(OCT1) 
rs34447885 Ser14Phe Reduced Vmax  [11, 13] 
rs72552761 Gln18His    
 rs34570655 Leu23Val    
 rs35888596 Gly38Asp    
 rs2297373 Phe41Leu    
 rs12208357 Arg61Cys Reduced uptake Increased AUC & Cmax Decreased Vd 
[10, 11, 13] 
 rs35546288 Leu85Phe Similar function  [13] 
 rs55918055 Cys88Arg Reduced uptake  [10] 
 rs683369 Leu160Phe Similar function Reduced diabetes risk in metformin-treated patients [10, 11, 13] 
 rs34104736 Ser189Leu Reduced Vmax  [11, 13] 
 rs36103319 Gly220Val Reduced uptake  [11, 13] 
!! 7!
 dbSNP ID Mutation In vitro In vivo References 
 rs4646277 Pro283Leu Reduced uptake  [14] 
 rs4646278 Arg287Gly Reduced uptake  [14] 
 rs2282143 Pro341Leu Similar function No impact [11, 13, 15] 
 rs34205214 Arg342His Similar function  [11, 13] 
 rs34130495 Gly401Ser Reduced Vmax Increased Km 
Increased glucose half-life 
following metformin treatment [10, 11, 13] 
 rs628031 Met408Val Similar function Positive predictor for efficacy of metformin [11, 13, 15] 
 rs72552762 Gly414Ala    
 rs202220802 Met420del Reduced Vmax Increased Km 
Increased glucose half-life 
following metformin treatment [10, 11, 13] 
 rs35956182 Met440Ile    
 rs34295611 Val461Ile Similar function  [13] 
 rs34059508 Gly465Arg Reduced uptake Increased glucose half-life following metformin treatment [11, 13] 
!! 8!
 dbSNP ID Mutation In vitro In vivo References 
 rs35270274 Arg488Met Similar function  [11, 13] 
SLC22A2 
(OCT2) 
rs72552765 Phe45Leu    
rs8177505 Phe45Ile    
 rs8177504 Pro54Ser Similar function  [16] 
 rs8177509 Phe161Leu Similar function  [16] 
 rs8177507 Met165Ile Reduced Vmax  [17] 
 rs8177508 Met165Val Similar function  [16] 
 rs57371881 Arg176His    
 rs201919874 Thr199Ile Reduced Vmax Increased Cmax and AUC [18, 19] 
 rs145450955 Thr201Met Reduced Vmax Increased Cmax and AUC [18, 19] 
 rs316019 Als270Ser Reduced Vmax Increased Cmax and AUC [17-19] 
 rs8177513 Ala297Gly Similar function  [16] 
 rs45599131 Leu351Trp    
 rs8177516 Arg400Cys Reduced Vmax  [17] 
 rs8177517 Lys432Gln Increased Km  [17] 
!! 9!
 dbSNP ID Mutation In vitro In vivo References 
 rs3907239 Arg463Lys    
 rs17853948 Val502Gly    
 rs17853948 Val502Glu    
SLC22A3 
(OCT3) 
rs8187715 Thr44Met Increased Vmax  [20] 
rs8187717 Ala116Ser Similar function  [20] 
 - Met370Ile Reduced Vmax  [21] 
 rs8187725 Thr400Ile Increased Km Reduced Vmax 
 [20] 
 - Val423Phe Increased Km Reduced Vmax 
 [20] 
 rs12212246 Ala439Val   [22] 
 rs9365165 Gly475Ser   [22] 
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rOct2 (Slc22a2) was cloned from rat kidney in 1996, and was later cloned in 
human, mouse, rabbit, and pig [1, 23]. Human OCT2 is mainly localized to the 
basolateral membrane of renal proximal tubules in the kidney; OCT2 is also expressed 
in small intestine, lung, placenta, brain, thymus, and inner ear [5]. Human OCT2 
transports model cations including TEA+, MPP+, ASP, N-methylnicotinamide, 
aminoguanidine; neurotransmitters such as dopamine (DA), epinephrine, 
norepinephrine (NE), serotonin (5-HT), histamine; and drugs including memantine, 
oxaliplatin, cimetidine, and metformin. OCT2 mediates the first step in renal excretion of 
many drugs; it also facilitates the passage of drugs across the BBB (as efflux 
transporter) and participates in the regulation of intracellular concentrations of 
neurotransmitters [5]. The efficacy of cationic drugs that are OCT2 substrates and are 
mainly excreted by the kidney can be improved by comedication of other OCT2 
substrates; down-regulated expression of OCT2 may lead to changes in 
pharmacokinetics and possible nephrotoxicity of OCT2 substrates [5]. Larger, and 
ethnically more diverse studies on OCT2 have revealed at least 10 cSNPs that altered 
transporter-substrate interactions [17]. Several functional studies of these 
polymorphisms have been conducted, and in vivo and in vitro changes in metformin 
disposition were observed (Table 1.1) [24]. 
hOCT3 (SLC22A3) and rOct3 (Slc22a3) were cloned in 1998 from human central 
nervous system and rat placenta, respectively, and was later cloned from mouse kidney 
[25-27]. The distribution of OCT3 is broad compared to OCT1 and OCT2; it is 
expressed in heart, skeletal muscle, brain, small intestine, liver, lung, kidney, urinary 
bladder, mammary gland, cornea, skin, blood vessels, and tumor cells [5]. In the CNS, 
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OCT3 has been detected in neurons, glial cells and epithelial cells of the choroid plexus 
[1, 22, 28, 29]. It is targeted to basolateral membranes of placental epithelium, to the 
sinusoidal membrane of hepatocytes, and to the luminal membrane of bronchial 
epithelial cells [1, 22, 28, 29]. Typical model cations for OCTs, neurotransmitters, and 
drugs such as metformin, are transported by OCT3. OCT3 is involved in the uptake of 
organic cations into brain, heart, and liver; it also participates in biliary excretion of 
organic cations, and changes neuronal activities and behavior by regulating 
neurotransmitter concentrations in the CNS [30]. OCT3 has been suggested to be 
related with coronary heart disease, prostate cancer, and obsessive-compulsive 
disorder in children [21, 31, 32]. Inhibitors of OCT3 may be employed to suppress 
cardiotoxicity of drugs that are OCT3 substrates [5]. At least seven SNPs were detected 
for human OCT3; however, evidence for functional consequences on metformin 
disposition is limited (Table 1.1) [9]. 
 
 
1.2 Organic Cation Transporter-Mediated Drug Interaction and Importance 
OCTs play a pivotal role in the absorption, tissue distribution, and excretion of a 
diverse array of substances, including drugs, toxins, environmental pollutants 
(xenobiotics), neurotransmitters and metabolic waste products [1]. hOCT1, hOCT2 and 
hOCT3 exhibit overlapping substrate specificities and are able to transport a large 
variety of organic cations (i.e., weak bases that are positively charged at physiological 
pH), and some non-charged compounds. Hundreds of important therapeutics have 
been identified as substrates and/or inhibitors of OCTs so far [1]. In vivo studies have 
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shown that genetic variations in OCT1 are associated with alterations in metformin 
pharmacokinetics (PK) and co-administration of cimetidine (hOCT inhibitor) decreased 
metformin renal clearance [11]. Based on the fact that hOCT3 is expressed on the 
basolateral membrane in hepatocytes, and that liver is a major organ for drug 
elimination (first pass effect), hOCT3 is also vital for affecting drug bioavailability, 
supported by a recent study showing that OCT3 plays an important role in the 
absorption and elimination of metformin [33]. Recently, hOCTs, especially hOCT2 and 
hOCT3 have been detected in the central nervous system, and speculated to be part of 
the extraneuronal monoamine transport system (uptake-2 system), responsible for the 
peripheral reuptake of monoamine neurotransmitters such as serotonin and 
norepinephrine [26, 34]. Changes in the level of neurotransmitters in the CNS is thought 
to be the reason for several neurological diseases including depression [35]. So, 
identifying hOCTs as new targets for treating these diseases is of importance and might 
offer breakthroughs in treatment since traditional antidepressant drugs targeting the 
uptake-1 system (e.g., serotonin transporter) are associated with either no response or 
side effects for a large number of patients [36].  
As these transporters have an impact on the pharmacokinetics (e.g., AUC, 
clearance and tissue distribution) of a broad variety of therapeutics, pharmacodynamic 
(PD) response might be altered due to concomitant administration of substrates or 
inhibitors of the same transporter. This is called drug-drug interaction (DDI), which might 
lead to unexpected side effects to patients. For instance, the glucose-lowering effect of 
metformin is decreased due to the co-administration of verapamil (hOCT1 inhibitor) [37]. 
Therefore, the United States Food and Drug Administration (FDA) and the European 
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Medicines Agency (EMA) have issued guidance documents regarding circumstances 
under which drug interactions with specified transporters need to be investigated for 
drug safety and efficacy [38, 39]. Specifically, investigated drugs should be evaluated in 
vitro to determine whether they are substrates of OCT2 when renal active secretion is 
important [38]. 
OCT substrates exhibit a wide variety of structural and physiochemical properties 
and currently the nature of the biochemical interactions between substrate and 
transporter are unknown. Polymorphisms that change the expression level, regulation, 
turnover, and/or substrate affinity of these transporters can potentially influence 
therapeutic efficacy and may cause toxic side effects of individual drugs [1]. 
Understanding the mechanism of substrate-transporter interaction and finding critical 
residues for that interaction may provide information for developing strategies for 
treating transporter related DDIs. In order to obtain a deeper understanding of drug 
transport through hOCTs and for designing drugs with optimized biodistribution, 
excretion and controlled drug-drug interactions, it is important to elucidate the structure 
of the substrate binding region, and through what mechanisms various substrates bind 
to the region [40]. In the end, these questions can only be solved by the crystallization 
of ligand-transporter complexes; however, no transporter of the SLC22 family been 
successfully crystallized. Therefore, identifying which amino acid residues are critical for 
transporter-substrate interactions though homology modeling is currently of central 
importance.  
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1.3 Current Perspectives of Homology Modeling 
New proteins important in biological pathways/processes are routinely 
discovered, and one of the major goals of structural biology involves formation of 
protein-ligand complexes, in which the protein molecules act energetically in the course 
of binding [41]. Understanding the structures of proteins is also essential for 
understanding the effects of disease mutations, for designing experiments to probe the 
mechanisms of substrate binding, and for guiding in silico drug design [42]. However, 
determining the structures of SLC22 transporters has proven difficult either through X-
ray crystallography, NMR spectroscopy, or electron microscopy due to their partially 
hydrophobic surfaces, flexibility, lack of stability, and inability to produce a large amount 
of pure protein [43]. In the absence of experimental data, model building on the basis of 
a known 3-dimensional structure of a homologous protein is at present the best 
available method to obtain structural information [41]. 
Homology modeling uses the fact that two evolutionarily related protein 
sequences have similar structures [44]. Thus, utilizing the known crystal structure 
(experimentally solved) of a protein as a template can help mimic the structure of a 
closely related protein whose structure is unknown. Currently, 83,546 experimental 
protein structures are available in Protein Data Bank (PDB) [45], and even though the 
number of solved crystal structures is steadily increasing, the rate is still far slower than 
the growth of newly discovered proteins [43]. Utilizing homology modeling is helping 
scientists bridge the gap between sequence and structure space with knowledge we 
possess [46]. Homology modeling provides knowledge for both medical and biological 
aspects, such as hypotheses about drug design, ligand binding site, substrate 
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specificity, molecular etiology of genetically transmitted disease related to SNPs, 
starting models for X-ray crystallography, and function annotation [41]. 
Homology modeling provides insights for structure of the target protein, the 
quality of which depends on the sequence similarity to the template [47]. Models of 
target proteins built on templates with more than 50% sequence similarities are 
accurate for drug discovery purposes, mutagenesis experiments can be guided based 
on models with 25 to 50% similarities to templates, and similarities between 10 to 25% 
are tentative [48-50]. Building a homology model is a multi-step process, which can be 
summarized as follows: (1) identification of template; (2) sequence alignment; (3) model 
building; (4) model refinement, and (5) model validation [51].  
Utilizing programs to compare the amino acid sequence of the query protein with 
sequences of proteins stored in PDB (structures solved) is the first step to identify a 
suitable template. The most frequently used server is BLAST (Basic Local Alignment 
Search Tool, NCBI) [52]. The sequences of the query protein and the chosen template 
are aligned to overlay the evolutionarily related blocks of the two proteins; this 
procedure is usually conducted with program ClustalX [53]. Possible error in alignment 
is the main source of deviation in homology modeling even when the correct template 
was used [41]. Once an alignment is built between the query and template, the template 
structure is used to guide the construction of a theoretical structure for the target 
protein. This model building entails two parts: first, for the portion of sequences aligned, 
the program only needs to adjust side-chain atoms of the template structure based on 
the amino acids of the target; second, for parts that are not aligned, either deletion or 
insertion will be performed. Generally rigid-body assembly, spatial restraint, segment 
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matching, and artificial evolution are used for model building [41]. The most widely used 
software to generate homology models is MODELLER (University of California at San 
Francisco, San Francisco, CA) [54]. After refining and validating the model with 
numerous scoring functions, information from a successfully generated model (after 
validation) could be used to guide other studies and experiments. The challenge in 
generating homology models for membrane transporters concerns utilizing templates 
with low sequence identity and/or similarity, and the divergent membrane topologies of 
transporters [55]. A list of crystal structure templates (identified through running 
alignment and choosing transporters with the highest sequence identities) 
recommended by the International Transporter Consortium to use for homology model 
generation for SLC transporters is shown below in Table 1.2 [56]. 
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Table 1.2 Recommended templates for homology modeling on SLC transporters 
[56]. 
 
Family Template 
SLC7 Amino acid antiporter AdiC 
SLC10 Apical sodium-dependent bile acid transporter ASBTNM 
SLC15 Peptide transporter PepTSO 
SLC22 High-affinity phosphate importer PiPT 
SLC28 Concentrative nucleoside transporter vcCNT 
SLC47 Multidrug and toxic compound extrusion transporter NorM 
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Over the past two decades, researchers have been conducting experiments to 
determine the structure and mechanisms of action for organic cation transporters. In the 
earlier days, transmembrane domains and secondary structures of OCTs were 
predicted with hydropathy profiles. Prior to building 3-D models for these transporters, 
determination of which amino acids to look into (and could potentially be involved in 
ligand-transporter interactions) were based on either the properties and locations of 
amino acids or whether residues are conserved within certain transporter type(s) [57-
59]. As a starting point of studying ligand-transporter (OCT) interactions, the Koepsell 
group first looked into residues that may be involved in cation transport in rOct1 in 1999 
by mutating an acidic amino acid that is conserved in OCTs but not in OATs – Asp475 
(presumably located in TMD 11) [57]. Changes in substrate transport property after 
residue substitution indicated that Asp475 might be a part of an interaction domain [57]. 
To look further into transporter-ligand interactions, the Koepsell group decided to 
identify amino acids of rOct2 that are responsible for the higher affinity towards 
corticosterone compared with the low affinity between rOct1 and corticosterone [58]. 
Through introducing polypeptide stretches of rOct2 into rOct1, exchanging amino acids 
between the two transporters, and measuring transport functions, amino acids that 
might be responsible for the high affinity of rOct2 to corticosterone were identified 
(Table 1.3) [58]. 
Due to the fact that 2-D topology models of OCTs could not provide visualization 
of the binding pocket, scientists began to generate three-dimensional models of OCTs 
with the help of several crystallized membrane transporters. From the year 2005, 3-D 
homology models of rOct1, rOct2, rbOct2 and hOCT2 have been reported in literature 
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using either lactose permease (LacY) from Escherichia coli (PDB ID: 1PV6) or glycerol-
3-phosphate transporter (Glp-T) from Escherichia coli (PDB ID: 1PW4) as template [40, 
60-62]. In 2005, Popp et al. looked into eighteen consecutive amino acids on the fourth 
TMD in rat Oct1 because this domain was hypothesized to contain amino acids on one 
side of the presumed α helix that are conserved within OCTs but not OATs. By 
introducing mutations to these residues and testing changes in TEA+ and MPP+ 
transport activity (substrate selectivity, affinity and turnover rates) in oocytes, three 
residues were identified as critical for TEA+ and MPP+ uptake [40]. Then they conducted 
homology modeling and generated an inward-open 3-D model for rOct1 using LacY as 
template, and claimed the localization of these residues inside the binding pocket [40]. 
In the same year, Zhang et al. conducted a study to identify amino acid 
residue(s) responsible for the difference in transport activity between rbOct1 and rbOct2 
[61]. Three amino acids on the C-terminal half that are conserved in OCT1 orthologs but 
different in OCT2 were mutated, and one residue (Glu447) was identified as a 
contributor to binding properties of rbOct2 [61]. Zhang et al. then built an inward-open 3-
D homology model of rbOct2 based on the crystal structure of Glp-T and confirmed that 
Glu447 faces and lie within the putative cleft region [61, 63]. 
Following their previous work, the Zhang group further elucidated hOCT2 
structure by examining the accessibility to hydrophilic thiol-reactive reagents [64]. Based 
on the homology model of rbOct2 built by Zhang et al. in a previous study, a 3-D 
homology model of human OCT2 (using GlpT as template) was generated [63, 64]. All 
cysteine residues in TMDs 10 and 11 were mutated and tested for transport activity 
changes (using TEA+) as well as accessibilities to biotin [64]. Results showed only 
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Cys474 is exposed to the extracellular aqueous environment, and “participates in 
forming a transport pathway for TEA+” [64]. Amino acid residues identified as critical for 
transporter-substrate interactions from 2-D topology modeling as well as 3-D homology 
modeling are summarized in Table 1.3. 
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Table 1.3. Critical residues identified through modeling studies. 
 
Transporter Model Template Critical Residue(s) Reference 
rOct1 2-D topology model - Asp475 [57] 
rOct2 2-D topology model - Ile443, Tyr447, Glu448 [58] 
rOct1 3-D homology model LacY Trp218, Tyr222, Thr226 [40] 
rOct2 3-D homology model LacY Cys451 [65] 
rbOct2 3-D homology model GlpT Glu447 [61] 
hOCT2 3-D homology model GlpT Cys474 [64] 
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From these past studies, we noticed that even though a number of amino acid 
residues have been identified as related to substrate selectivity and affinity, and are 
supported by experimental data, utilization of information from 3-D models of OCT 
transporters was kept to a minimum. These models were only used as a validation tool 
to confirm that the residues are close to the binding pocket. One of our purposes of 
generating a 3-D homology model of hOCT3 is to provide guidance in mutagenesis 
experiments and mechanism analyses, not just as an indicator for the probable location 
of certain residues. The 3-D homology models of OCTs built in earlier studies, albeit 
‘accurate’ at that time, are somehow out-of-date considering the low sequence identities 
(and low sequence similarities). What we need is to develop 3-D homology models for 
OCT3 with higher sequence identities/similarities, and utilize them to direct future site-
directed mutagenesis studies of OCT-ligand interaction, transport mechanism, novel 
drug designs and other important purposes. Choosing eukaryotic inorganic phosphate 
transporter (PiPT) as the template to conduct homology modeling for OCT3 is superior 
compared to the old templates (LacY and GlpT) because of its higher sequence 
similarity towards the target transporter (~40%), increasing the confidence of using the 
generated 3-D model to guide mutagenesis studies; crystal structures of LacY and GlpT 
are both inwardly oriented, whereas PiPT is crystallized in an occluded state that 
provides the most interactions between docking ligand and binding pocket; presence of 
a large intracellular loop between TMDs 6 and 7 in PiPT makes its structure more 
similar to that of an OCT, compared to the structures of LacY and GlpT that do not 
contain any large loop; moreover, LacY and GlpT belong to prokaryotic organisms while 
PiPT belongs to eukaryotic organisms, which makes PiPT closer to OCTs in an 
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evolutionary point of view. Based on these points and the fact that PiPT is 
recommended by the International Transporter Consortium, we decided to generate a 3-
D homology model of hOCT3 using PiPT as the template [56]. 
 
1.4 Species Differences for Organic Cation Transporter 3 
 OCT3 orthologs from human, rat, and mouse share a great deal of similarities 
including protein sequence, tissue distribution, operating mechanism, substrates, and 
so on; these similarities might be explained by the high sequence identity and similarity 
between the orthologs (with 87% between human and mouse OCT3 and 86% between 
human and rat OCT3, as shown in Figure 1.2 and Figure 1.3, respectively). Despite 
these similarities, inter-species differences are also observed. Rodent Oct3s are 
detected in some tissues where human OCT3 is not expressed (large intestine, spleen, 
thymus, etc.), and interacting characteristics for some molecules with OCT3 orthologs 
could be quite diverse (as shown in Table 1.4), which could be used to distinguish 
OCT3 from different species [1]. 
 Even though the differences between transporter sequences are trivial, they 
could lead to diverse conformations of the transporters expressed in cell membranes, 
which might be the cause of different transporter-ligand interacting profiles. 
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Table 1.4 Substrate* and inhibitor affinities (in µM) for different OCT3 orthologs. 
 
Molecule hOCT3 mOct3 rOct3 Reference 
Corticosterone 0.12  4.9 [26, 66] 
Dopamine 1200  384,620 [26, 67, 68] 
Estradiol 2.9  1.1 [66, 69] 
Norepinephrine 2630*  432 [26, 70] 
o-Methylisoprenaline 4.4 1.4  [69, 71] 
Serotonin 1000  970 [26, 70] 
Cimetidine 17 1.3  [72] 
Procainamide 738 11  [27, 73] 
Quinine 37 3.0  [29, 73] 
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Figure 1.2 Sequence alignment between human and mouse OCT3. 
 
Query sequence represents human OCT3 and subject sequence represents mouse 
Oct3. 
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Figure 1.3 Sequence alignment between human and rat OCT3. 
 
Query sequence represents human OCT3 and subject sequence represents rat Oct3. 
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1.5 Organic Cation Transporter-Mediated Neurotransmitter Disposition in Brain 
 Depressive disorders are among the most serious and burdensome psychiatric 
illnesses in the world, costing billions of dollars each year in US alone [74]. Previous 
studies have proved that neurotransmitter levels are low in depressive disorder patients. 
Current treatment is focusing on maintaining monoamine neurotransmitter (serotonin 
and/or norepinephrine) levels in synaptic clefts by inhibiting high affinity, low capacity 
monoamine uptake-1 transporters (e.g., serotonin transporter (SERT), norepinephrine 
transporter (NET), dopamine transporter (DAT), Figure 1.4) with serotonin transporter 
reuptake inhibitors (SSRIs, e.g., fluoxetine) and serotonin and norepinephrine 
transporter reuptake inhibitors (SNRIs, e.g., venlafaxine). However, this approach could 
end up with undesirable side effects, delayed onset of action, and poor response to the 
treatment [75, 76]. There are currently no new strategies for diagnosing or treating 
depressive disorders, so scientists are focusing on the low affinity, high capacity 
(uptake-2) clearance pathway for biogenic amines – the backup system for monoamine 
neurotransmitter clearance. Increasing evidence has indicated that organic cation 
transporters, which are widely expressed in the CNS (human OCT expression 
summarized in Table 1.5), interact not only with catecholamine (a kind of monoamine 
related to depressive disorders), but also with DA, 5-HT and NE and likely play a role in 
the regulation of neurotransmitter homeostasis, indicating that OCTs, especially OCT2 
and OCT3, could be the major components of uptake-2 system (Figure 1.4) [34, 76]. 
Studies using inhibitors and knockout mice have been conducted to explore the role of 
OCTs in depression. Feng et al. noticed a dose-dependent increase in 5-HT level when 
administering decynium-22 (D-22, an OCT inhibitor), suggesting that OCTs might be 
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important in adaptive neurophysiological and behavioral response regulations [77]. Oct3 
mRNA level as well as protein expression in SERT knockout mice were significantly 
increased in hippocampus when D-22 was given to SERT knockout mice; 
antidepressant-like effects were also observed, while mOct1 mRNA level remained 
unchanged [30, 78]. In another study, infusing antisense mouse Oct3 oligonucleotides 
to mice ventricle resulted in decreased expression of Oct3 and correlated 
antidepressant-like effects such as decreased immobility during forced swim test, and 
so on. [79]. These data suggest that OCT3 might be a compensatory mechanism for 
dysfunctional 5-HT clearance, an important determinant of CNS monoamine 
neurotransmitter balance, and a novel target for depressive disorder therapy. 
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Figure 1.4 Inhibition of monoamine neurotransmitter pathway(s) in treating 
depressive disorders [76]. 
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Table 1.5 Expression of OCTs in human brain. 
 
Tissue Transporter Level Expression Localization Technique References 
Choroid 
Plexus 
hOCT1 mRNA +  RT-PCR [80] 
hOCT2 mRNA +  RT-PCR [80] 
hOCT3 mRNA +  RT-PCR [80] 
Brain 
Capillary 
hOCT1 
mRNA +  RT-PCR [81, 82] 
Protein + Luminal and abluminal side of BMECs Confocal microscopy & western blot [83] 
hOCT2 
mRNA +/-  RT-PCR [81, 82] 
Protein + Luminal and abluminal side of BMECs Confocal microscopy & western blot [83] 
hOCT3 
mRNA +  RT-PCR [81, 82] 
Protein +  Confocal microscopy & Western blot [82] 
Neuron 
and Glia 
Cells 
hOCT1 mRNA -  Northern blot [84] 
hOCT2 
mRNA 
+ Neurons Northern blot, in situ hybridization & Western blot [84, 85] 
Protein 
!! 31!
Tissue Transporter Level Expression Localization Technique References 
 hOCT3 
Protein + Neurons Immunohistochemistry [86] 
mRNA 
+ Astrocytes RT-PCR & immunohistochemistry [85, 86] 
Protein 
Different 
Brain 
Regions 
hOCT1 mRNA -  Northern blot [84] 
 hOCT2 mRNA + Amygdaloideus nucleus Northern blot 
[84] 
  mRNA + Caudatus nucleus Northern blot 
  mRNA + Cerebral cortex In situ hybridization 
  mRNA 
+ Hippocampus Northern blot, in situ hybridization & Western blot 
  Protein 
  mRNA + Subthalamicus nucleus Northern blot 
  mRNA + Substantia nigra Northern blot 
!! 32!
Tissue Transporter Level Expression Localization Technique References 
  mRNA + Thalamus Northern blot  
 hOCT3 mRNA + Caudate nucleus RT-PCR [87] 
  mRNA + Cerebellum RT-PCR  
  mRNA + Cerebral cortex RT-PCR  
  mRNA + Medulla oblongata RT-PCR  
 
 
mRNA + Nucleus accumbens RT-PCR 
 
 mRNA + Hippocampus RT-PCR 
 mRNA + Substantia nigra RT-PCR 
 mRNA + Pons RT-PCR 
 
+: indicates transporter expression 
-: indicates no transporter expression detected 
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Chapter 2 
Research Objectives and Specific Aims 
 
 
2.1 Research Objectives 
To identify and verify crucial amino acid residues for interactions at the substrate-
binding pocket of hOCT3, which will support breakthroughs in understanding drug 
absorption, clinical drug-drug interaction, compound extraction, as well as inform 
rational drug design strategies for hOCT3 interacting drugs. Our hypothesis is that 
substitution of hOCT3 residues involved in transporter-substrate interactions, implicated 
through in silico molecular modeling and docking studies, will result in altered affinity 
(Km) of the transporter to MPP+. Further, comparing critical residues of human, mouse, 
and rat OCT3 orthologs may provide an explanation for species differences in 
transporter function. 
 
2.2 Specific Aims To Address the above Hypotheses 
2.2.1 To identify residues critical for transporter-substrate interactions using in silico 3-D 
homology modeling and substrate docking. A 3-D model of hOCT3 is required for 
predicting substrate binding site and critical residuals. 
2.2.2 To test the hypothesis that the critical residues predicted in the model are involved 
in hOCT3 substrate recognition. The affinity of the transporter (Km) for MPP+ should be
!! 34!
altered upon substitution of the true critical residues. 
2.2.3 To test the hypothesis that substrates structurally divergent from MPP+ will have 
different/additional amino acids critical for hOCT3 interaction. Additional substrate 
docking, mutational and kinetic studies should be performed to further validate the 
model. 
2.2.4 To test the hypothesis that inter-species transport differences among human, 
mouse and rat OCT3 orthologs result from differences in the architecture of their binding 
regions. 
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Chapter 3 
IDENTIFICATION OF hOCT3 STRUCTURAL ELEMENTS IMPACTING 
TRANSPORTER-SUBSTRATE INTERACTIONS 
 
 
3.1 Introduction 
 Organic cation transporters belong to the solute carrier 22 (SLC22) family and 
mediate the absorption, distribution, and elimination of a broad variety of endogenous 
and exogenous organic compounds [1, 88]. OCTs are widely expressed in many barrier 
organs, such as intestine, kidney, liver, and brain [1, 88]. In the intestine, OCT1 and 
OCT3 are targeted to the brush border membrane of enterocytes and mediate the entry 
of cationic compounds [1]. OCT1 and 3 are both expressed in the sinusoidal membrane 
of hepatocytes to mediate the first step of hepatic excretion of substrates [1]. OCT2 and 
3 are expressed in the basolateral membrane of proximal tubule cells and govern the 
first step of renal excretion [1]. Hundreds of important clinical therapeutics as well as 
numerous endogenous compounds are known substrates and/or inhibitors of OCTs, 
including metabolites (e.g., creatnine), neurotransmitters (e.g., serotonin, 
norepinephrine), hormones (e.g., corticosterone), receptor antagonists (e.g., 
cimetidine), chemotherapeutics (e.g., cisplatin), antidiabetics (e.g., metformin), and so 
on [1]. 
 Intensive attention has been paid to study the interactions between (as well as 
transport mechanism of) compounds with OCT1 and OCT2 because of the large 
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amount of transporter expression in liver and kidney of these two transporters, 
respectively. However, more and more groups are focusing on OCT3, which is the most 
widely expressed organic cation transporter (expressed in tissues including skeletal 
muscle, placenta, heart and many more) [1]. Knockout mouse models showed the 
importance of Oct3 in different tissues. Intravenous injection of the OCT substrate MPP+ 
into Oct3 knockout mice resulted in significantly reduced drug levels in heart and fetus, 
suggesting a prominent role of mOct3 in the heart and feto-placental interface [89]. A 
similar conclusion was drawn from a study of samples from patients with heart disease, 
which suggested that hOCT3 is important for the disposition and action of cationic drugs 
in the myocardium [90]. A compensatory up regulation of Oct3 in the brain of mice that 
lack the neuronal serotonin transporter indicated that mOct3 could play a role in 
neurotransmitter uptake [30, 78]. A recent study has demonstrated the high expression 
level of OCT3 in adipose tissue, and its ability to regulate extraneuronal norepinephrine 
uptake [91]. In human, OCT3 has been suggested to be related with coronary heart 
disease, prostate cancer, and obsessive-compulsive disorder in children [21, 31, 32, 
90]. These possible physiological roles of OCT3 as well as numerous studies about 
interactions between clinical therapeutics and OCT3 justifies the importance of this 
transporter and the need to study its working mechanism. 
In order to understand hOCT3-substrate interactions, structure of the transporter 
is needed, however, no member of the SLC22 family has been successfully crystallized. 
Thus there is a need to generate a 3-D homology model of hOCT3 with a suitable 
template. So far, three-dimensional homology models of rOct1, rOct2, rabbit (rb) Oct2, 
and hOCT2 have been reported in literature [40, 60-62]. Even though in vitro studies 
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were conducted and identified several amino acid residues that might be critical in terms 
of substrate and/or inhibitor interactions with these transporters, the models these 
groups generated were based on templates sharing low sequence identities to OCT, no 
ligand has been docked to the binding pockets of these models, and they were only 
used to demonstrate the locations of identified residues, not as guidance to direct 
mutational studies. 
In our study, we generated a 3-D homology model for hOCT3 using eukaryotic 
inorganic phosphate transporter (PiPT) as the template. Based on information of the 
predicted amino acid residues through homology modeling and docking, we further 
tested accuracy of the model by mutating the implicated amino acids to see if the 
residue substitution altered the affinity between substrate and transporter. After 
confirming the mutants with sequencing, mutant plasmids were introduced to 
mammalian cells through stable transfection, and finally changes in transporter-
substrate interaction were quantified via saturation assays. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Tritiated 1-methyl-4-phenylpyridinium ([3H]MPP+) was purchased from 
PerkinElmer Life and Analytical Science (Waltham, MA), and unlabeled MPP+ was 
obtained from Sigma-Aldrich (St. Louis, MO). QuikChange Lightning Site-Directed 
Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA). 
Lipofectamine® 2000 Transfection Reagent was purchased from ThermoFisher 
Scientific (Waltham, MA). QIAprep Spin Miniprep Kit and QIAprep Spin Midiprep Kit 
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were purchased from QIAGEN Inc. (Germantown, MD). GoTaq Green Master Mix was 
purchased from Promega (Madison, WI). Abcam Plasma Membrane Protein Extraction 
Kit (ab65400) was purchased from Abcam (Cambridge, MA). DYKDDDDK Tag 
(D6W5B) Rabbit mAb antibody, and Anti-rabbit IgG AP-linked antibody were purchased 
from Cell Signaling Technology (Beverly, MA). Na+/K+-ATPase α1 (N-15) antibody (sc-
16041) was purchased from Santa Cruz Biotechnology (Dallas, TX). 
3.2.2 Modeling and Docking 
The three-dimensional homology model of hOCT3 was based on the crystal 
structure of a eukaryotic inorganic phosphate transporter (PiPT) [92]. PiPT belongs to 
the phosphate: H+ symporter family of MFS, similar to the SLC22 family, PiPT also 
contains 12 TMDs and intracellular N and C termini, and a large intracellular loop 
between TMDs 6 and 7 [93]. The crystal structure of PiPT (PDB ID: 4J05) was solved in 
complex with its substrate, inorganic phosphate, by Pedersen et al. at a resolution of 2.9 
Å in an occluded conformation [92]. The structure of PiPT is currently recommended as 
the best template for OCTs and OATs because it is a crystallized transporter sharing 
the most sequence similarity with the human solute carrier group at this time, it 
possesses similar structure compared with OCTs (previous OCT templates do not 
contain the large intracellular loop), it was crystallized in an occluded state (could 
provide more information for compound docking), and PiPT is more evolutionarily close 
to OCTs and OATs. Based on these factors, we chose to use PiPT as the template to 
generate a 3-D homology model for hOCT3 [56]. 
Sequence of hOCT3 was obtained from Universal Protein Resource database 
(UniProt, accession code: O75751), and the sequence of PiPT was downloaded from 
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PDB in a fasta file (4J05) [94, 95]. The template and target (hOCT3) sequences were 
aligned using ClustalX followed by manual adjustments based on the TMDs observed in 
PiPT structure and predicted for hOCT3 using ICM Browser (Molsoft LLC) and Phobius 
(Stockholm Bioinformatics Center), the result of alignment is shown in Figure 3.1 [53, 96, 
97]. The extracellular loop of PiPT was not part of the crystallization, thus it was not 
contained in the sequence of the PDB file; the extracellular and intracellular loops 
between TMDs 1, 2 and 6, 7 of hOCT3 were truncated because no corresponding 
residues were modeled in the crystal structure of PiPT. 
Next, 100 homology models of hOCT3 were generated based on the alignment 
result and the crystal structure of PiPT (downloaded from PDB) using the MODELLER 
software (University of California at San Francisco, San Francisco, CA) [54, 95]. A 
DOPE (discrete optimized protein energy) score was automatically calculated for each 
model, and it was used to evaluate the quality of a structure model as a whole. 
Stereochemical quality of a 3-D protein model was checked using the PROCHECK 
function, which produces a Ramanchandran plot that helps visualize energetically 
allowed regions, and analyzes the residue-by-residue geometry of a model. A model 
with more than 90% of amino acids located in the favorable regions of a 
Ramanchandran plot is generally considered as an acceptable model. The binding 
pocket of hOCT3 for a specific docking compound was identified using GOLD suite 5.4 
by docking a compound into a 12-Å sphere surrounding residue Asp478 (critical residue 
identified in earlier studies) [57]. Docking was performed by first energy-minimizing the 
docking compound (substrates for hOCT3, including MPP+, serotonin, metformin, 
tetrapentylammonium (TPA+), and epinephrine, chemical structures shown in Figure 3.2) 
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using Tripos force field with Gasteiger-Hückel charges in SYBYL X, and then inserting 
the compound with 10 poses into the pre-defined sphere for each of the one hundred 
models using GOLD [95, 98]. GOLD’s default scoring function was used to determine 
the best ligand binding mode (pose), then potentially important amino acid residues 
were identified by analyzing the structure within the binging pocket as well as binding 
interaction energies. 
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Figure 3.1 Sequence alignment between PiPT and hOCT3. 
 
Asterisks (*) indicate residues that are the same between the template and the target; 
colons (:) represent residues that are highly conserved between the sequences; periods 
(.) represent residues that are weakly conserved between the sequences; and blanks 
indicate that the residues are different. 
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Figure 3.2 Structures of other docking compounds for hOCT3. 
 
Structures of other docking compounds MPP+ (A), serotonin (B), metformin (C), TPA+ 
(D) and epinephrine (E) are displayed, respectively. 
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3.2.3 DNA Quantification 
 Concentration and purity of DNA samples were determined using GeneQuant 
Spectrophotometer. 
3.2.4 Transformation 
Plasmid DNA of hOCT3 was provided by Dr. Grundemann, the cDNA of hOCT3 
is located in vector pcDNA3. Competent DH5α cells (50 µL) were thawed on ice and 
aliquoted to a pre-chilled tube, then 5 ng plasmid DNA was added to the cells and 
gently mixed. Mixture was kept on ice for 30 min before heat shocking for 30 s in 42 °C 
water bath. After adding 950 µL pre-warmed (42 °C) LB broth (Sigma-Aldrich, St. Louis, 
MO), the tube was kept on ice for 2 min, then shaken for 1 hr at 250 rpm at 37 °C. 
Different volumes of the mixture were plated on LB-ampicillin (100 mg/mL) agar plates 
and kept in 37 °C incubator overnight. Ampicillin-resistant colonies were selected and 
grown in growth media for further experimentation. 
3.2.5 Plasmid DNA Extraction 
Transformed competent cells were added to 5 mL LB broth containing ampicillin 
(100 mg/mL) and shaken overnight at 200 rpm, 37 °C. Cells were pelleted by 
centrifuging at 5000 rpm for 5 min (could be stored at -20 °C). QIAprep Spin Miniprep 
Kit was used to extract plasmid DNA from cells, the procedure has been described in 
the protocol [99]. Cell pellet was thoroughly re-suspended with 250 µL of chilled buffer 
P1 [Tris, EDTA, glucose and RNase A], then lysed by mixing with 250 µL buffer P2 
[NaOH and SDS], and neutralized with 350 µL buffer N3 [KAc]. The mixture was 
centrifuged for 10 min at 13,000 rpm, and the supernatant (about 800 µL) was applied 
to QIAprep spin column. Column was centrifuged for 1 min at 13,000 rpm, and after 
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discarding the flow through, 750 µL buffer PE [Tris, and ethanol] was applied, then the 
column was centrifuged for 1 min at 13,000 rpm twice to discard the flow through 
completely. QIAprep column was placed in a clean 1.5 mL microcentrifuge tube, and 50 
µL buffer EB [NaCl, Tris, and isopropanol] was added to the center of the column and 
let stand for 1 min before a final 1 min centrifugation at 13,000 rpm to elute plasmid 
DNA. 
3.2.6 Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed according to the protocol of 
QuikChange Lightning Site-Directed Mutagenesis Kit [100]. Reagents were added to 
PCR tubes according to Table 3.1, and PCR was performed with cycles setup as 
conditions in Table 3.2. Sequences of the primers for each mutation reaction are 
summarized in Table 3.3.  Dpn I restriction enzyme (2 µL) was added to the mixture 
after PCR reaction and incubated at 37 °C for 5 min, while 45 µL XL 10-Gold 
Ultracompetent cells (thawed on ice) were aliquoted to a pre-chilled 14-mL BD Falcon 
polypropylene round-bottom tube. 2-mercaptoethanol (2 µL) was added to the 
competent cells and incubated on ice for 2 min before 2 µL of the enzyme-treated 
plasmid DNA was added, then the reaction was incubated on ice for 30 min. The 
transformation mixture was heat shocked for 45 s at 42 °C before 500 µL NZY+ broth 
(ThermoFisher Scientific, Waltham, MA) was added. The reaction was incubated on ice 
for 2 min and the tube was shaken for 1 hr at 250 rpm in 37 °C. Different volumes (50-
200 µL) of the mixture were plated on LB-ampicillin (100 mg/mL) agar plates and kept in 
37 °C incubator overnight. Ampicillin-resistant colonies were selected and grown in 
growth media for sequencing and other further experimentation.  
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Table 3.1 Reagent setup for site-directed mutagenesis. 
 
Reagent Amount 
10* Reaction buffer 5 µL 
Plasmid template (5 ng/µL) 5 µL 
Oligonucleotide primer #1 (100 ng/µL) 1.25 µL 
Oligonucleotide primer #2 (100 ng/µL) 1.25 µL 
dNTP mix 1 µL 
QuikSolution reagent 1.5 µL 
ddH2O 35 µL 
QuikChange Lightning enzyme 1 µL (added last) 
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Table 3.2 PCR cycle parameters. 
 
Cycles Temperature Time 
1 95 °C 2 min 
18 95 °C 20 s 
 60 °C 10 s 
 68 °C 4 min 
1 68 °C 5 min 
 4 °C hold 
 
	  	   47	  
Table 3.3 Sequences for mutagenesis primers. 
 
Mutation Site Direction Sequence (5’ – 3’) 
Phe36Ala Forward AGACCACGCCGACGGCGAGGAAGGCGAAGG 
 Reverse CCTTCGCCTTCCTCGCCGTCGGCGTGGTCT 
Phe36Tyr Forward ACGCCGACGTAGAGGAAGGCGAAGGTG 
 Reverse CACCTTCGCCTTCCTCTACGTCGGCGT 
Val40Ala Forward GTGCCCAGGAAGGCCACGCCGACGA 
 Reverse TCGTCGGCGTGGCCTTCCTGGGCAC 
Val40Leu Forward GTGCCCAGGAAGAGCACGCCGACGAAG 
 Reverse CTTCGTCGGCGTGCTCTTCCTGGGCAC 
Trp358Ala Forward CACCACTGCGCTTGTGAACGCAGCAAACATAAGAATAAGTG 
 Reverse CACTTATTCTTATGTTTGCTGCGTTCACAAGCGCAGTGGTG 
Trp358Phe Forward CCACTGCGCTTGTGAAGAAAGCAAACATAAGAATAAGTGTGC 
 Reverse GCACACTTATTCTTATGTTTGCTTTCTTCACAAGCGCAGTGG 
Trp358Tyr Forward CCACTGCGCTTGTGAAGTAAGCAAACATAAGAATAAGTGTGC 
 Reverse GCACACTTATTCTTATGTTTGCTTACTTCACAAGCGCAGTGG 
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Mutation Site Direction Sequence (5’ – 3’) 
Glu451Ala Forward CTGAATTTACCAAATAAACAATTGCAAAGGCCATGGTTATCCCTAG 
 Reverse CTAGGGATAACCATGGCCTTTGCAATTGTTTATTTGGTAAATTCAG 
Glu451Asp Forward TAGGGATAACCATGGCCTTTGATATTGTTTATTTGGTAAATTCAGA 
 Reverse TCTGAATTTACCAAATAAACAATATCAAAGGCCATGGTTATCCCTA 
Asp478Glu Forward TGTTCAGGTCTGTGTGAGTTTGGGGGAATCATAGC 
 Reverse GCTATGATTCCCCCAAACTCACACAGACCTGAACA 
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3.2.7 DNA Sequencing 
DNA sequencing was performed by Genewiz using Sanger DNA sequencing 
technique (South Plainfield, NJ). Samples containing 10 µL plasmid DNA (80 ng/µL) 
and 5 µL specific primer (5 pmol/µL) were pre-mixed and shipped to Genewiz. 
Sequencing results were retrieved electronically. 
3.2.8 Tissue Culture 
Chinese hamster ovary (CHO) cells were maintained at 37 °C with 5% CO2 in 
DMEM F-12 medium (Mediatech Inc., Herndon, VA) containing 10% FBS and 1% 
penicillin/streptomycin. 
Stably transfected CHO cells expressing hOCT3 (CHO-hOCT3), hOCT3 
mutants, as well as empty vector, were established in this study. All transfected cell 
lines were maintained at 37 °C with 5% CO2 in DMEM F-12 medium containing 10% 
FBS, 1% penicillin/streptomycin, and 250 µg/mL G418.  
3.2.9 Transfection 
Stable transfection was performed according to the Lipofectamine® 2000 
Reagent protocol [101]. One day before transfection, 8*104 cells/well CHO cells were 
seeded in 12-well tissue culture plates. On the day of transfection, a mixture of 
Lipofectamine® 2000 (4 µL/well) and OptiMEM medium (96 µL/well, ThermoFisher 
Scientific, Waltham, MA) was made by mixing the two ingredients, then the mixture was 
incubated for 5 min at room temperature. Transfection plasmid DNA (1 µg, 1 µg/µL) was 
added to 100 µL OptiMEM medium and mixed with 100 µL of Lipofectamine® 2000-
OptiMEM medium mixture, then incubated for 20 min at room temperature. Old medium 
in each well was replaced with new DMEM F-12 medium containing 10% FBS and 1% 
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penicillin/streptomycin, the 200 µL mixture was then added to each well after incubation 
and mixed by gentle shaking. The plates were kept in a 37 °C incubator with 5% CO2, 
and G418 (1 mg/ml) was applied to transfected cells for selection. Cells were lifted from 
wells and kept in flasks after patches of G418 resistant cells have been established 
(successful selection against non-transfected cells). 
3.2.10 Cellular Uptake Assay 
The procedure for the cellular uptake assay was adapted from that previously 
published [94]. Two days before cellular uptake experiment, 2*105 cells/well were 
seeded in 24-well tissue culture plates and grown in the absence of antibiotics. On the 
day of experiment, cells were equilibrated in transport buffer at room temperature (22-
25 °C) for 10 min [500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, 
pH 7.4]. After equilibrium, this solution was replaced with 500 µL of fresh transport 
buffer containing either unlabeled MPP+ (1 µM) spiked with [3H]MPP+ (0.25 µCi/mL) in 
the presence or absence of inhibitor, or [3H]MPP+ (0.25 µCi/mL) with increasing 
concentrations (1 to 200 µM) of unlabeled MPP+ for the times indicated. At the end of 
the incubation, the cells were quickly rinsed three times with ice-cold transport buffer 
and lysed with 200 µL NaOH (1 N). After shaking for two hours, mixture was neutralized 
with 250 µL HCl (1 N) and 200 µL HEPES (0.01 M). The radioactivity of cell lysate (400 
µL from each well) was quantified by liquid scintillation counting, and the uptake profile 
was normalized by the total protein content measured by the Bradford method. The 
cellular uptake of substrates was shown as picomoles of substrate per milligram total 
protein. All uptake data were corrected for background accumulation in corresponding 
empty vector transfected control cells. Kinetic calculations were performed using 
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GraphPad Prism Software version 5.0 (GraphPad Software Inc., San Diego, CA). The 
Michaelis-Menten constant (Km) was calculated using nonlinear regression. Results 
were confirmed by repeating all experiments at least three times with triplicate wells for 
each data point in every experiment. 
3.2.11 Transformation Confirmation 
Cells were grown in T-75 flasks before experiment and trypsinized for collection. 
Cells were suspended in 500 µL lysis buffer [1 M Tris (pH 8.0), 5 M NaCl, 0.5 M EDTA, 
and 10% SDS] containing proteinase K (0.4 mg/mL) and incubated at 55°C while 
shaking overnight. Genomic DNA was thoroughly extracted from samples with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) after vigorously shaking for 10 
min, and centrifuged for 10 min at 15,000 g. The upper aqueous phase was carefully 
transferred to a fresh tube. After adjusting salt concentration with NaAc, 0.7 volumes of 
isopropanol was added and mixed well, then the mixture was centrifuged immediately at 
15,000 g for 30 min to get the DNA pellet. The pellet was washed with 70% ethanol and 
resuspended with TE buffer [10 mM Tris (pH 8.0), and 1 mM EDTA]. 
Genomic DNA (2 ng), Master Mix (5 µL), as well as 1 µL primer pair mix (T7 and 
hOCT3-REV1) were added in a PCR reaction with cycles setup as conditions in Table 
3.4. PCR products were loaded to 1% agarose gel for separation using electrophoresis 
at 120 V for 60 min, and visualized with UV light box after ethidium bromide staining. 
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Table 3.4 PCR cycle parameters. 
 
Cycles Temperature Time 
1 95°C 2 min 
18 95°C 30 s 
 50°C 30 s 
 72°C 3 min 
1 72°C 5 min 
 4°C hold 
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3.2.12 Western Blot Assay 
The gel for western blot was cast on the same day of the experiment according 
to the recipe shown in Table 3.5. Plasmid membrane protein and cytosolic protein were 
extracted from hOCT3, hOCT3 mutant as well as empty vector transfected CHO cells 
according to Abcam plasma membrane protein extraction kit protocol [102]. Protein 
concentrations of the samples were quantified with Bradford method. Plasma 
membrane protein from each sample (30 µg) was prepared, volume of the samples was 
adjusted to the same with phosphate buffer [1 M NaH2PO4, 1 M Na2HPO4], and 5× SDS 
loading buffer [10% 2-mercaptoethanol, 150 mM Tris, 5% SDS, 25% glycerol, 0.05% 
bromphenol blue, DI water] was added before the sample was boiled in water for 5 min 
or incubated in 37 °C water bath for 30 min. After loading the ladder and samples onto 
the gel, electrophoresis was conducted by applying a current for 60 min at 170 V. The 
proteins were transferred to PVDF (or nitrocellulose) membrane by applying 
electrophoresis at 100 mAmps for 60 min, then the membrane was blocked with 5% 
BSA for 1 hr at room temperature. Membrane was incubated with primary antibody 
(1:200 with 5% BSA) overnight at 4 °C, and washed with 1× TBS for 3 times (10 min 
each). Membrane was then incubated with secondary antibody (1:200 with 5% BSA) for 
2 hr at room temperature, and washed with 1× TBS for 3 times. NBT/BCIP substrate 
(diluted with AP buffer, Roche Diagnostics, Indianapolis, IN) was applied to the 
membrane for protein visualization. 
3.2.13 Statistics 
Data are reported as mean ± SD. Statistical differences were analyzed using 
one-way ANOVA followed by Dunnett’s post-hoc t-test (α=0.05).  
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Table 3.5 Recipe for western blot gel. 
 
Running gel Stacking gel 
Reagent Volume Reagent Volume 
H2O 1.65ml H2O 2.83ml 
30% Acrylamide mix 1.3ml 30% Acrylamide mix 0.54ml 
1M Tris (pH 8.8) 1.95ml 1M Tris (pH 6.8) 0.5ml 
10% SDS 50ul 10% SDS 40ul 
10% fresh APS 50ul 10% fresh APS 40ul 
TEMED 6ul TEMED 6ul 
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3.3 Results 
3.3.1 Homology modeling of human organic cation transporter 3 
 GOLD scores of the top ten docked poses of MPP+ in the binding pocket of 
hOCT3 are summarized in Table 3.6 along with their corresponding DOPE scores. The 
largest GOLD score represents the best docking pose, and the smallest DOPE score 
demonstrates the best homology model. Since our focus was on the binding interaction 
between docking substrate and hOCT3, our model selection criteria was primarily based 
on the GOLD score, and by comparing the DOPE scores of these models with top 
GOLD scores, we noticed that Model 10 not only had the best GOLD score, its DOPE 
score was also lower than most of the other top ranked models. Thus we chose Model 
10 as our best 3-D homology model for hOCT3. The generated 3-D homology model is 
shown in Figure 3.3 (viewing from extracellular side of the membrane) along with the 
hypothesized binding pocket; a 2-dimensional demonstration of the topology of this 
hOCT3 model across plasma membrane is shown in Figure 3.4, and amino acid 
residues forming the MPP+ binding pocket are highlighted. 
PROCHECK analysis of the selected hOCT3 model generated a Ramachandran 
plot for the model (Figure 3.5). Ramachandran plot provides a way to visualize 
energetically allowed regions for backbone torsion angles psi against phi of amino acid 
residues in protein structure; the plot demonstrates the empirical distribution of data 
points (amino acid residues) observed in a single structural model. In a Ramachandran 
plot, amino acids are distributed in four regions – most favored region (red), additional 
allowed region (yellow), generously allowed region (light yellow) and disallowed region 
(white). For this hOCT3 model, 83.8% of amino acids were in the most favored region, 
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12.7% in the additional allowed region, and only a total of 3.5% in the generously and 
disallowed region (disallowed residues highlighted in Figure 3.4). These observations 
imply that the structure of our model for hOCT3 is plausible. 
	  	   57	  
Table 3.6 GOLD and DOPE scores for hOCT3. 
Model identifier GOLD score DOPE score 
Model 10 51.70 -47556.887 
Model 93 51.04 -47705.746 
Model 40 50.66 -47517.859 
Model 21 48.98 -47247.949 
Model 46 48.80 -47451.941 
Model 35 48.21 -46998.316 
Model 19 48.15 -47372.027 
Model 24 47.61 -47997.582 
Model 72 47.30 -47882.953 
Model 51 47.02 -47385.375 
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Figure 3.3 3-D homology model of hOCT3. 
 
Transmembrane domains are depicted as ribbons in different colors in sequence 
(numbered 1 – 12) and hypothesized binding pocket is shown as ‘surface’ in the middle. 
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Figure 3.4 2-D topology of hOCT3 across plasma membrane. 
 
Highlighted amino acids (red) are residues forming the binding pocket, and might be 
involved with hOCT3-substrate interactions; amino acids in black are residues identified 
to be in the disallowed region in the Ramanchandran plot. 
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Figure 3.5 Ramachandran plot of hOCT3. 
 
Phi and psi indicate backbone conformation torsion angles of amino acid residues, 
which represent the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino 
acids are laid out in different regions: most favored region (red), additional allowed 
region (yellow), generously allowed region (light yellow), and disallowed region (white). 
Residues depicted in red squares are in the generously allowed and disallowed regions. 
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Visualizing the generated homology model for hOCT3 in Pymol, we were able to 
identify all the amino acid residues surrounding and forming the large binding pocket 
responsible for MPP+ docking in the transporter. These residues are from different 
transmembrane domains that intertwine and form the binding region: TMD 1 (Phe36, 
Val37, Val40, Phe41), TMD 2 (Leu161, Asn162, Phe165), TMD 4 (Tyr227, Val230), 
TMD 5 (Met248), TMD 7 (Trp358, Ala362, Tyr365, Gln366, Val369, Met370), TMD 10 
(Arg443, Thr447, Glu451), and TMD 11 (Ser474, Cys477, Asp478) (Figure 3.6). 
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Figure 3.6 3-D demonstration of binding pocket for MPP+ in hOCT3. 
 
Residues forming the binding pocket are depicted as yellow sticks. 
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3.3.2 Critical residues identified through substrate docking 
To support our modeling study, MPP+ (prototypical substrate for OCTs) was 
energy minimized in SYBYL X using Tripos force field with Gasteiger-Hückel charges 
and docked to the binding pocket of hOCT3 model to identify amino acid residues 
critical for MPP+-hOCT3 interactions in GOLD suite 5.4.  
 From the docking result, the protonated aromatic ring of MPP+ was detected to 
be interacting with the negatively charged glutamic acid residue in the pocket (Asp478) 
through H-bond interaction (Figure 3.7). Moreover, the pyridinium ring and the benzene 
ring of MPP+ were seen to be interacting with Phe36, Val40, Trp358, and Glu451 in 
aromatic or hydrophobic manners (Figure 3.7), these interactions are summarized in 
Table 3.7. 
OCTs are polyspecific transporters, i.e. they have the ability to interact with and 
transport molecules of different structures. Thus we also investigated hOCT3 
interactions with several other substrates showing structural diversity from MPP+ 
through energy minimization and docking. Identified amino acid residues that could 
potentially affect substrate-transporter interactions, as well as their interaction types are 
summarized in Table 3.7, and shown in Figure 3.8. Comparing the amino acid residues 
identified for each docking compound, we have noticed that all identified residues could 
be located in the binding pocket defined for MPP+ (Figure 3.6), several ‘critical’ residues 
were common among certain compounds while others were unique for specific 
substrate(s). This indicates that the docked substrates would likely bind to the same 
pocket in the transporter and their specific binding regions may overlap, but these 
regions are not exactly the same.  
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Figure 3.7 MPP+ docked in the substrate binding region of hOCT3. 
 
The ligand (MPP+, green) and ‘critical’ amino acid residues (yellow) are displayed as 
sticks. The dashed line indicates the H-bond interaction between the protonated 
aromatic ring of MPP+ and the negatively charged residue Asp478. 
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Table 3.7 MPP+ docking result summary for hOCT3. 
 
Docking substrate Amino acid residue Type of interaction 
MPP+ Phe36 Edge face interaction 
 Val40 Hydrophobic interaction 
 Trp358 Edge face interaction 
 Glu451 Edge face/arene-H interaction 
 Asp478 H-bond interaction 
Serotonin Val40 Arene-H interaction 
 Asn162 Side-chain donor 
 Met248 Side-chain acceptor 
 Asp478 Side-chain acceptor 
Metformin Met248 Side-chain acceptor 
 Trp358 Arene-H interaction 
 Ser474 Backbone acceptor 
 Asp478 Side-chain acceptor 
TPA+ Trp358 Arene-H interaction 
Epinephrine Phe36 Arene-H interaction 
 Val40 Arene-H interaction 
 Asn162 Side-chain donor 
 Met248 Side-chain acceptor 
 Gln366 Side-chain donor 
 Cys477 Side-chain acceptor 
 Asp478 Side-chain acceptor 
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Figure 3.8 Other compounds docked in the substrate binding region of hOCT3. 
 
The ligands (green) – serotonin (A), metformin (B), TPA+ (C), and epinephrine (D), as 
well as ‘critical’ amino acid residues (yellow) are displayed as sticks, and summarized in 
Table 3.5. 
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3.3.3 Critical residue substitution 
 To test our model predictions and if the residues identified are indeed critical for 
MPP+-hOCT3 interactions, both conservative and non-conservative (Figure 3.9, [103]) 
substitutions were introduced to these positions to detect changes in hOCT3 affinity for 
MPP+. Both single mutants and double mutants were generated. The substitutions for 
each residue are listed in Table 3.8. 
Since there is no commercially available hOCT3 antibody with consistent 
performance, we added a FLAG tag (a short piece of peptide with sequence 
DYKDDDDK) after the last amino acid of hOCT3 (before the stop codon) in order to 
perform immunoblotting on hOCT3 protein for successive studies; the scheme is shown 
in Figure 3.10. Using the QuikChange Lightning Site-Directed Mutagenesis Kit along 
with PAGE-purified oligo primers specifically designed for each site, substitutions were 
performed and later on confirmed through DNA sequencing (sequencing results for the 
mutated sites shown in Figure 3.11). 
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Figure 3.9 Recommended conservative amino acid substitution scheme [103]. 
 
Residues roughly equivalent are grouped together in five subsets, which generally 
correlate with side-chain physicochemical properties. 
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Table 3.8 Summary of critical residue substitutions. 
 
 Critical residue Substitution 
Single mutants Phe36 Tyr 
  Ala 
 Val40 Leu 
  Ala 
 Trp358 Phe 
  Tyr 
  Ala 
 Glu451 Asp 
  Ala 
 Asp478 Glu 
Double mutants Phe36Tyr & Val40Leu 
 Phe36Tyr & Glu451Ala 
 Val40Leu & Glu451Ala 
 
 
 
 
 
Figure 3.10 Scheme for adding FLAG tag to hOCT3. 
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Figure 3.11 Sequencing results for mutants. 
 
Figures were cropped from sequencing results for hOCT3-FLAG mutants Phe36Tyr (A), 
Phe36Ala (B), Val40Leu (C), Val40Ala (D), Trp358Phe (E), Trp358Tyr (F), Trp358Ala 
(G), Glu451Asp (H), Glu451Ala (I), Asp478Glu (J), and Phe36TyrVal40Leu (K), with the 
highlighted parts indicating the substituted sites. 
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3.3.4 Critical residue confirmation 
Upon successful stable transfection of wild type hOCT3 (both regular and FLAG-
tagged) as well as generated hOCT3 mutants, we performed an initial screening on the 
transfected cell lines to detect MPP+ transport activity (Figure 3.12). Stably transfected 
non-FLAG hOCT3 wild type-expressing (CHOhOCT3) cells showed marked 
accumulation of MPP+ (~3.5 fold) compared to empty vector transfected (pcDNA3.1, 
CHO-EV) background control cells (11.0 ± 0.2 vs. 3.4 ± 1.5 pmol/mg protein/10 min, 
respectively). FLAG-tagged hOCT3 wild type-expressing (CHOhOCT3-FLAG) cells 
exhibited ~7 fold accumulation of MPP+ (22.7 ± 0.3 pmol/mg protein/10 min) as 
compared to CHO-EV cells. The known OCT inhibitor quinine (200 µM), showed 
virtually complete inhibition of hOCT3-mediated MPP+ uptake (Figure 3.12). Cell 
accumulation assay demonstrated that the residue substitutions Val40Ala, Trp358Ala, 
Trp358Phe, Trp358Tyr, Asp478Glu, and double mutant Phe36TyrGlu451Asp almost 
completely abolished the transport activity of hOCT3 for MPP+, while the other mutant 
hOCT3s expressed some level of MPP+ transport (Figure 3.12). This indicates that 
residues Trp358 and Asp478 are extremely critical for the interactions between hOCT3 
and MPP+ during the transport process, since a mild change in that specific amino acid 
(conservative substitution) destroyed transport activity for MPP+. 
Next, for variants still demonstrating MPP+ transport activity, dose-response 
studies were performed to estimate Km values and confirm any changes as compared to 
wild type hOCT3 (Figure 3.13, Table 3.8). Comparing the Km values of wild type hOCT3 
and FLAG-tagged wild type hOCT3, we noticed that adding the FLAG tag did not 
significantly alter the affinity of hOCT3 for MPP+ (16 ± 2.2 vs. 18.4 ± 1.7 µM, 
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respectively) (Figure 3.13, Table 3.9). Comparing the Km values of hOCT3 mutants to 
that of the two wild type hOCT3s (wild type and FLAG-tagged wild type hOCT3), we 
observed that Phe36Ala, Val40Leu, Glu451Ala, and Val40Leu-Glu451Ala mutations 
resulted in significantly decreased transporter affinity for MPP+ (Figure 3.13, Table 3.9), 
whereas Phe36Tyr, Glu451Asp, and Phe36Tyr-Val40Leu mutations did not significantly 
change the affinity for MPP+ (Figure 3.13, Table 3.9). Also by comparing the Km values 
of transporter mutants of the same residue, we noticed that substituting the amino acid 
to alanine (non-conservative substitution) clearly decreased affinity of the transporter for 
MPP+ to a larger extent than the conservative mutant; in one case, the non-conservative 
substitution completely diminished MPP+ transport (Val40Ala) (Figure 3.12). The 
changes in transporter affinity for MPP+ suggest that all of these identified residues are 
involved in the interaction between hOCT3 and MPP+. 
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Figure 3.12 Functional screening of wild type and mutant hOCT3 transfected CHO cell lines. 
 
The concentration of MPP+ was 1 µM, and the concentration of quinine was 200 µM; incubation time was 10 min. Values 
are mean ± SD of triplicate values. * denotes p<0.05 as determined by one-way ANOVA followed by Dunnett’s t-test.
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Figure 3.13 Dose-response curves for MPP+ on wild type and mutant hOCT3. 
 
Michaelis-Menten kinetics of MPP+ transport in (A) hOCT3, (B) hOCT3-FLAG, (C) 
hOCT3-FLAG-Phe36Ala, (D) hOCT3-FLAG-Phe36Tyr, (E) hOCT3-FLAG-Val40Leu, (F) 
hOCT3-FLAG-Glu451Ala, (G) hOCT3-FLAG-Glu451Asp, (H) hOCT3-FLAG-
Phe36TyrVal40Leu, and (I) hOCT3-FLAG-Val40LeuGlu451Ala transfected CHO cells. 
Representative data showing 1 min uptake of MPP+ measured in stably transfected 
CHO cells in the presence of increasing concentrations of MPP+ (1 to 200 µM) are 
shown. Data were corrected for nonspecific background measured in empty vector 
control cells and are means ± SD of triplicate values. Km values were determined with 
nonlinear regression and the “Michaelis-Menten” model in GraphPad Prism software.  
  
!! 75!
Table 3.9 Summarized Km values of MPP+ for wild type and mutant hOCT3. 
 
Transporter type Km (µM) 
hOCT3 16.0 ± 2.2 
hOCT3-FLAG 18.4 ± 1.7 
hOCT3-FLAG-Phe36Ala 29.1 ± 2.0* 
hOCT3-FLAG-Phe36Tyr 14.6 ± 0.5 
hOCT3-FLAG-Val40Leu 32.2 ± 4.3* 
hOCT3-FLAG-Glu451Ala 40.9 ± 4.8* 
hOCT3-FLAG-Glu451Asp 23.4 ± 3.9 
hOCT3-FLAG-Phe36TyrVal40Leu 14.4 ± 1.7 
hOCT3-FLAG-Val40LeuGlu451Ala 70.0 ± 9.7* 
Km values were expressed as mean ± SD from triplicate determinations. 
* denotes significant difference between wild type and mutant hOCT3 Km values p < 
0.05 as determined by two-tailed Student’s unpaired t-test. 
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3.3.5 Plasmid DNA detection of non-functional hOCT3 mutants 
To prove the success of stable transfection of cell lines exhibiting no MPP+ 
transport activity, genomic DNA from specific transfected cell lines was extracted and 
amplified through PCR using primer pairs that recognize both ends of hOCT3 cDNA 
(amplicon size~1.7 kb). Bands shown in Figure 3.14 with sizes about 1.7 kb proved the 
success of transfection as well as existence of hOCT3 cDNA in tested cell lines (one 
wild type, one hOCT3 mutant with MPP+ transport activity, and all non-functional hOCT3 
mutants). 
3.3.6 Immunodetection of non-functional hOCT3 mutants 
To examine the presence of transporter protein in the plasma membrane, 
western blot assays were conducted. Utilizing both hOCT3- and FLAG-targeting primary 
antibodies, cytosolic and plasma membrane protein fractions were probed under 
various conditions. Unfortunately, we were not able to detect any OCT3 signal. 
However, immunodetection of β-actin in the cytosolic fractions was successful (Figure 
3.15), indicating proper technique. Refinement of hOCT3 western blot protocol is 
ongoing. 
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Figure 3.14. PCR result for genomic DNA of mutant cell lines. 
TriDye 1 kb DNA Ladder located in lane 1, followed by wild type hOCT3 (lane 2), 
hOCT3 mutant with transport activity (lane 3), and all non-functional mutants (lane 4 to 
lane 9). 
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Figure 3.15. Western blot result for wild type and mutant hOCT3 cell lines. 
 
Western blot image showing the detection of β-actin (43 kD) in membrane and cytosolic 
fractions of wild type and mutant hOCT3 cell lines.  
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3.3.7 Homology modeling and docking of mutant hOCT3 
 To further test the performance of our hOCT3 model and the importance of 
identified residues, novel 3-D homology models of one functional mutant transporter 
(hOCT3-Val40Leu) as well as three of the nonfunctional mutant transporters (hOCT3-
Val40Ala, hOCT3-Trp358Tyr, and hOCT3-Asp478Glu) were generated. MPP+ was 
again used as the docking compound to identify any potential interaction between the 
ligand and the binding pocket. Docking results are shown in Figure 3.15 as well as 
Figure 3.16 (A), (B), and (C) respectively. 
In the hOCT3-Val40Leu model, all of the amino acid residues (Phe36, Trp358, 
Glu451, and Asp478; except for the substituted residue at position 40, Figure 3.16) 
identified as ‘critical’ for MPP+-hOCT3 interactions were still predicted to be interacting 
with MPP+ in similar manners (summarized in Table 3.10). In contrast, the substituted 
amino acid (Leu40) was farther away from the docked ligand (MPP+), thus the 
probability of interaction between Leu40 and MPP+ is greatly reduced (Figure 3.16). For 
the other residues, although still identified as critical, their interactions with MPP+ were 
not as strong compared with the residues in the wild type model. The distance between 
the negatively charged atom in Asp478 and the positively charged atom in MPP+ was 
longer in the mutant model (2.5 Å vs. 2.2 Å in the wild type hOCT3 model), and 
aromatic interactions between MPP+ and other residues were weaker (as shown in 
Figure 3.16). Thus the decreased affinity for Val40Leu mutant could be a result of 
slightly altered binding pocket conformation after residue substitution, which changed 
interaction strengths between MPP+ and the transporter. 
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Figure 3.16 Structure of MPP+ docked in hOCT3-Val40Leu mutant. 
 
Structure of MPP+ (green) docked in the substrate binding region of hOCT3-Val40Leu 
model. The ligand (green) and ‘critical’ amino acid residues (yellow) are displayed as 
sticks, as well as Leu40 (pink). 
  
!! 81!
Table 3.10 MPP+ docking result summary for hOCT3-Val40Leu. 
 
Amino acid residue Type of interaction 
Phe36 Arene-H interaction 
Trp358 Edge face interaction 
Glu451 Edge face/arene-H interaction 
Asp478 H-bond interaction 
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To determine the possible reason for loss of MPP+ transport activity in non-
functional hOCT3 mutants, MPP+ was docked to the binding pocket of each mutant 
model, and residues interacting with the ligand were identified (Figure 3.17). 
Interestingly, similar patterns were observed for all three models. In the hOCT3-
Val40Ala model, only Phe479 was identified to interact with MPP+ through an arene-H 
interaction; in the hOCT3-Trp358Tyr model, only Phe359 was identified to interact with 
MPP+ through an arene-H interaction; and in the hOCT3-Asp478Glu model, only Arg20 
was identified to interact with MPP+ through π-π stacking interaction (Figure 3.17). All 
other residues in the three binding pockets were either far apart from the ligand or only 
slightly interacting with MPP+ in hydrophobic manners (Figure 3.17). None of these 
three ‘critical’ residues was predicted to be interacting with MPP+ in the wild type 
hOCT3 model, and they are not part of the residues that form the binding pocket in the 
model, either. All three of the substituted residues were located farther away from MPP+ 
(data not shown), and thus could not interact with the compound. Therefore, based on 
the models, amino acid substitutions that led to complete loss of MPP+ transport activity 
changed the confirmation of MPP+ binding pockets to a large extent and weakened the 
interacting strengths between residues and MPP+. 
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Figure 3.17 Structure of MPP+ docked in non-functional hOCT3 mutants. 
 
Structure of MPP+ (green) docked in the substrate binding region of hOCT3-Val40Ala 
(A), hOCT3-Trp358Tyr (B), and hOCT3-Asp478Glu (C) models. The ligand (green) and 
‘critical’ amino acid residues (yellow) are displayed as sticks. 
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3.4 Discussion 
 Recently, more and more attention has been paid to study the interactions 
between (as well as transport mechanism of) compounds with hOCT3 [1]. The possible 
physiological roles of hOCT3 (suggested to be related with prostate cancer, coronary 
heart disease, and obsessive compulsive behavior), the most widely expressed organic 
cation transporter (expressed in skeletal muscle, placenta, heart, brain, and many more 
tissues), as well as numerous studies about interactions between clinical therapeutics 
and hOCT3 justify the importance of this transporter and the need to study its working 
mechanism. 
Due to the lack of an X-ray crystal structure of any member of the SLC22 family, 
generating a 3-D homology model for hOCT3 with a suitable template is of importance. 
Homology models of some other OCT transporters (rOct1, rOct2, rbOct2, and hOCT2) 
have been reported in the literature [40, 60-62]. In vitro experiments were conducted in 
these studies, and several amino acid residues that might be critical in terms of 
substrate and/or inhibitor interactions with these transporters have been identified 
(summarized in Table 1.3 together with residues identified using 2-D topology models of 
OCTs). The 3-D homology models for these OCT transporters, albeit ‘accurate’ at that 
time, are ‘out of date’ considering they were generated based on templates sharing 
lower sequence identities to OCT (LacY or GlpT). 
Therefore, in the present study, a homology model for hOCT3 was generated 
using an inorganic phosphate transporter PiPT, recently identified as a superior 
template compared to LacY and GlpT, as the template [92]. Docking the model with a 
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prototypical OCT substrate, MPP+, a binding pocket for MPP+ that nested in the plasma 
membrane was identified, together with amino acids that formed the pocket (Figure 3.4).  
Residues ‘critical’ for MPP+-hOCT3 interactions were identified in this study, and 
a series of CHO cell lines stably expressing hOCT3 mutants (‘critical’ residues 
substituted) were established. Conservative substitutions at Trp358 and Asp478, along 
with non-conservative substitution at Val40, completely abolished the MPP+ transport 
activity of mutant hOCT3. For mutants that still possess MPP+ transport activity, we 
observed significantly increased Km value for several hOCT3 mutants (hOCT3-
Phe36Ala, hOCT3-Val40Leu, and hOCT3-Glu451Asp), indicating a decreased affinity 
between mutant transporters and MPP+, and the residues identified are contributing to 
the interactions between MPP+ and hOCT3. Substitutions (conservative and/or non-
conservative) on all residues hypothesized to be critical in MPP+-hOCT3 interactions led 
to significant changes in hOCT3 affinity to MPP+, which demonstrates that our model is 
valid and could be used as guidance towards future mutational studies to learn about 
other hOCT3-ligand interactions. Cell lines with double mutant transporters were also 
generated, which resulted in one abolishment in MPP+ transport (hOCT3-Phe36Tyr-
Val40Leu), decreased transport affinity for one other double mutant (hOCT3-Val40Leu-
Glu451Ala), and one double mutant with no significant affinity change (hOCT3-
Phe36Tyr-Val40Leu). Based on these results, importance of each identified residue 
could be ranked: Trp358, Asp478 > Val40 > Phe36, Glu451.  
In order to rule out the possibility that the loss of MPP+ transport activity was due 
to failure of transfection, protein translation or targeting of transporter protein to plasma 
membrane, PCR and western blot assays were performed. Genomic DNA from non-
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functional mutant cell lines was extracted and genomic integration of the intact cDNA for 
hOCT3 was confirmed using PCR and gel electrophoresis (Figure 3.14). Western blots 
of mutant transporter proteins (extracted from plasma membrane of the stably 
transfected cell lines) were performed, however, to date have been unsuccessful 
(Figure 3.15).  
A 3-D homology model of one of the mutant transporters (hOCT3-Val40Leu) with 
decreased affinity for MPP+ was generated using the same protocol. The same amino 
acids critical for MPP+-hOCT3 interactions were identified in the mutant model, but 
interacts with MPP+ were reduced, and Leu40 (the substituted residue) did not interact 
with the ligand. Homology models of hOCT3 mutants with no MPP+ transport activity 
were also generated and docked with energy-minimized MPP+. Interactions between 
MPP+ and mutant binding pockets were predicted to be weaker compared to wild type 
hOCT3, and the conformation of binding pockets were altered due to residue 
substitution, which could be the reason for loss of ability to transport MPP+. Docking the 
wild type hOCT3 model with ligands that are structurally divergent from MPP+ 
suggested that substrates of hOCT3 with distinct structures interact with different 
residues inside one large binding pocket, and their individual regions may overlap. 
Prior to constructing 3-D models for OCTs, 2-dimensional topology models of 
OCTs were used for transporter studies. In 1999, Koepsell’s group identified residue 
Asp 475 as being involved with TEA+ transport in rOct1 by mutating an acidic amino 
acid that is conserved in OCTs but not in OATs [57]. This negatively charged aspartate 
residue is located inside the binding pocket of our hOCT3 model (Figure 3.4, Figure 3.6) 
and identified to be interacting with a number of compounds in this study. In 2005, the 
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same group identified residues responsible for the discrepancy in corticosterone 
transport between rOct1 and rOct2 by introducing polypeptide stretches of rOct2 into 
rOct1, and exchanging amino acids between the two transporters (residues summarized 
in Table 1.3) [58]. Only one out of the three residues (Glu451) is located inside the 
binding pocket of our hOCT3 model; while the other two amino acids are both one 
residue apart from the opening of the pocket [58]. However, amino acids are not 
conserved between rOct1/rOct2 and hOCT3 in this area, and the affinity of hOCT3 to 
corticosterone is significantly higher compared with rOct1 (750 fold) and rOct2 (20 fold), 
so it is likely that the binding site for corticosterone in hOCT3 is different from that in 
rodent Octs [58]. 
With the generation of crystallized membrane transporters, in 2005, a 3-D 
homology model of rOct1 was developed using LacY as the template [40]. Popp et al. 
looked into eighteen consecutive amino acids on the fourth TMD in rat Oct1 by 
introducing mutations to these residues and testing changes in TEA+ and MPP+ 
transport activity in oocytes. Three residues were identified as critical for TEA+ and 
MPP+ uptake (Table 1.3) [40]. These residues are conserved in OCTs, however, are not 
part of the residues identified in this study that form the binding pocket for hOCT3. This 
information suggests that the binding pockets for rOct1 and hOCT3 are different, and 
could be supported by our study on one of these residues (hOCT3-Trp223Tyr mutant 
did not exhibit significant change in MPP+ transport activity, data not shown).  
In the same year, Zhang et al. conducted a study to identify amino acid 
residue(s) responsible for the difference of transport activity between rbOct1 and rbOct2 
by mutating three residues that are conserved in OCT1 but not in OCT2, and the 
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glutamate residue (Glu451, conserved and identified in hOCT3 model) was identified to 
be involved with TEA+-rbOct2 interactions [61].  
A cysteine residue (Cys451) critical for choline transport activity in rOct2 was 
identified by Sturm et al. in 2007 [65]. This non-conserved residue in hOCT3 (Tyr454) 
was not identified as part of the binding pocket. However, since hOCT3 affinity for 
choline is very low, and we have already suggested that hOCT3 is likely to have a 
different binding pocket than rOct2, this residue discrepancy is not too surprising. 
Following their previous work, Zhang et al. further elucidated hOCT2’s structure 
by examining the accessibility of binding sites to hydrophilic thiol-reactive reagents [64]. 
Based on the homology model of rbOct2 built by the same group in a previous study, a 
3-D homology model of hOCT2 (using GlpT as template) was generated [63, 64]. All 
cysteine residues in TMDs 10 and 11 were mutated and tested for transport activity 
changes (using TEA+) as well as accessibility to biotin [64]. Results showed that only 
Cys474 is exposed to the extracellular aqueous environment, and ‘participates in 
forming a transport pathway for TEA+’ [64]. The homology model in their study was in an 
inward-open facing state, unlike our model for hOCT3, which is in an occluded state 
[64]. So it is possible that this water accessible cysteine residue is buried inside 
transmembrane domains when the model is in an occluded state (when a substrate is 
covered by residues in the binding pocket). Thus, even though this conserved cysteine 
residue (Cys450) was not identified in our hOCT3 model, it is possible that it could be 
interacting with TEA+ (e.g. during substrate recognition), and this can be tested through 
further mutational studies in hOCT3. 
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No residue that is subject to non-synonymous SNP has been identified to be 
responsible in forming the binding pocket of hOCT3, however, one of the naturally 
occurring SNPs, Gly475Ser, is located close to the binding pocket (one amino acid 
away) [22]. Thus this residue substitution has the possibility of changing the 
conformation of the binding pocket and altering the binding affinities for certain 
compounds, which needs to be investigated. 
In summary, a 3-D homology model of hOCT3 was successfully generated. A 
ligand binding pocket, as well as residues that form the pocket, were determined. 
Residues related to MPP+ transport were confirmed by conducting uptake assays for 
respective mutants. 3-D homology models for four hOCT3 mutants were generated, and 
interacting residues were identified through docking with MPP+. These results suggest 
that hOCT3 substrates with different structures bind to different regions in one large 
binding pocket, and residues directly interacting with ligands may overlap. Further, loss 
of transport activity for MPP+ could be explained by lack of strong interactions between 
ligand and binding pocket residues. Comparison between our hOCT3 model and early 
OCT models indicates that the binding pockets of OCTs likely are not the same, 
although similarities do exist. These results and information about ligand binding in 
hOCT3 could someday be utilized to help with the development of potent substrates 
and/or inhibitors, as well as with the study of transport mechanisms. 
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Chapter 4 
SPECIES COMPARISON OF ORGANIC CATION TRANSPORTER 3 THROUGH 
HOMOLOGY MODELING 
 
 
4.1 Introduction 
In addition to humans, organic cation transporter 3 is also found in other species 
including mouse and rat, and plays similar roles in these species as well. OCT3/Oct3 
orthologs from human, rat, and mouse share a great deal of similarities including tissue 
distribution, operating mechanism, substrates, inhibitors, and so on, which is likely 
explained by the high sequence identity (and similarity) between the orthologs (with 
87% between human and mouse OCT3/Oct3 and 86% between human and rat 
OCT3/Oct3) [1]. Despite these similarities, differences do exist; for example, rodent 
Oct3s are detected in some tissues where hOCT3 is not expressed (large intestine, 
spleen, thymus) and interacting characteristics for some molecules with OCT3 orthologs 
can be quite diverse (as shown in Table 1.4). Utilizing transporter-substrate/inhibitor 
affinity differences, OCT3 orthologs from different species can be distinguished [1]. 
Even though the differences between transporter sequences are trivial, they 
could lead to diverse confirmations of the transporters, which might completely 
differentiate transport abilities among the three species, or differences between the 
binding sites of the transporters. Both of these might be the cause of different molecule-
transporter interacting profiles. Considering the fact that OCT3 transport profiles of
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different species are not completely distinct, the affinities between transporters and 
substrates/inhibitors are only significantly different in a few of the compounds, it is likely 
that the conformations for these orthologs are similar, with only the binding pockets 
exhibiting a few discrepancies. 
To test the hypothesis that the inter-species differences between human, mouse, 
and rat OCT3 orthologs are due to differences in their binding regions, homology 
models of mOct3 and rOct3 were built utilizing the same template (PiPT) and compared 
with the model of hOCT3. Compounds with significantly different affinities for these 
transporters were docked into the models; both the binding pockets and interacting 
residues were compared among species. 
 
4.2 Methods 
3-D homology models of mouse and rat Oct3 were generated based on the 
crystal structure of a eukaryotic inorganic phosphate transporter (PiPT) [92]. PiPT is a 
membrane of the phosphate: H+ symporter family of MFS. Similar to the SLC22 family, 
PiPT also contains 12 TMDs and intercellular termini, the 12 TMDs of PiPT are divided 
into two parts with 6 helices each (N and C domain), where the two parts are connected 
by a large intracellular loop [92]. The crystal structure of PiPT (PDB ID: 4J05) was 
solved in complex with its substrate, inorganic phosphate, by Pedersen et al. at a 
resolution of 2.9 Å in an occluded conformation [92, 95]. The structure of PiPT is 
currently recommended as the best template for OCTs and OATs because it is a 
crystallized transporter sharing the most sequence similarity with the human solute 
carrier group at this time, it possesses similar structure compared with OCTs (previous 
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OCT templates do not contain the large intracellular loop), crystallized in an occluded 
state (could provide more information for compound docking), and PiPT is more 
evolutionarily close to OCTs. Based on all this information, we are choosing it as the 
template to generate models for mouse and rat Oct3 [56]. 
Sequences of mouse and rat Oct3 were obtained from Universal Protein 
Resource database (UniProt, accession code: Q9WTW5, O88446), and the sequence 
of PiPT was downloaded from PDB in a fasta file (4J05) [95, 104, 105]. The template 
and target (mOct3 and rOct3) sequences were aligned with ClustalX followed by 
manual adjustments based on the TMDs observed in PiPT structure and predicted for 
rodent Oct3s using ICM Browser (Molsoft LLC) and Phobius (Stockholm Bioinformatics 
Center), the result of alignment is shown in Figure 4.1 [53, 96, 97]. The extracellular 
loop of PiPT was not part of the crystallization, and thus was not contained in the 
sequence of the PDB file; the extracellular and intracellular loops between TMDs 1, 2 
and 6, 7 of OCT3 were truncated because no corresponding residues were modeled in 
the crystal structure of PiPT. 
Then, one hundred 3-D homology models of both mOct3 and rOct3 were 
generated based on the alignment result and the crystal structure of PiPT (downloaded 
from PDB) using the MODELLER software (University of California at San Francisco, 
San Francisco, CA) [54]. A DOPE score was automatically calculated for each model, 
and it was used to evaluate the quality of a structure model as a whole. Stereochemical 
quality of a 3-D protein model was checked using the PROCHECK function, which 
produces a Ramanchandran plot that helps visualize energetically allowed regions, and 
analyzes the residue-by-residue geometry of a model. A model with more than 90% of 
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amino acids located in the favorable regions of a Ramanchandran plot is generally 
considered as an acceptable model. The binding pockets of mOct3 and rOct3 for 
specific docking compound(s) were identified using GOLD suite 5.4 by docking a 
compound into a 12-Å sphere surrounding residue Asp478 (critical residue identified in 
earlier studies) [57]. Docking was performed by first energy-minimizing the docking 
compound (substrates and inhibitor for OCT3, including MPP+, procainamide, or 
norepinephrine, chemical structures shown in Figure 4.2) using Tripos force field with 
Gasteiger-Hückel charges in SYBYL X, and then inserted the compound with 10 poses 
into the pre-defined sphere for each of the one hundred models using GOLD [26, 27, 70, 
73, 95, 98]. GOLD’s default scoring function was used to determine the best ligand 
binding mode (pose), then potentially important amino acid residues were identified by 
analyzing the structure within the binging pocket as well as binding interaction energies. 
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Figure 4.1 Sequence alignment of PiPT, mOct3 and rOct3. 
 
Asterisks (*) indicate residues that are the same between the template and the target; 
colons (:) represent residues that are highly conserved between the sequences; periods 
(.) represent residues that are weakly conserved between the sequences; and blanks 
indicate that the residues are different. 
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Figure 4.2 Structures of docking compounds for species differentiation. 
 
Structures of other docking compounds procainamide (A) and norepinephrine (B) are 
displayed, respectively. 
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4.3 Results 
4.3.1 Homology modeling of mouse organic cation transporter 3 
GOLD scores of the top ten docked poses of MPP+ in the binding pocket of 
mOct3 are summarized in Table 3.6 along with their corresponding DOPE scores. The 
largest GOLD score represents the best docking pose, and the smallest DOPE score 
demonstrates the best homology model. Since our focus was on the binding interaction 
between docking substrate and mOct3, our model selection criteria was primarily based 
on the GOLD score, and Model 5 had a significantly higher GOLD score compared to 
other models. Comparing the DOPE scores of these models with top GOLD scores, we 
noticed that even though Model 5 did not have the lowest score, the value was 
acceptable and lower than most of the other top ranked models. Thus we chose Model 
10 as our best 3-D homology model for mOct3. Visualizing the generated homology 
model for mOct3 in Pymol, we were able to identify all the amino acid residues 
surrounding and forming the large binding pocket for MPP+ in the transporter. The 
generated 3-D homology model along with the amino acid residues forming the MPP+ 
binding pocket are depicted as yellow sticks (Figure 4.3). These residues are from 
different transmembrane domains that intertwine and form the binding region for MPP+: 
TMD 1 (Arg19, Arg20, Leu23), TMD 2 (Leu158, Leu161), TMD 4 (Met219, Thr220, 
Val223), TMD 5 (Met243), TMD 7 (Phe354, Val358), TMD 10 (Tyr449, Leu450, 
Ser453), and TMD 11 (Ser466, Gly470, Leu471, Asp473, Phe474, Ile477, Phe481) 
(Figure 4.3). 
PROCHECK analysis of the selected mOct3 model generated its Ramachandran 
plot (Figure 4.4). Ramachandran plot provides a way to visualize energetically allowed 
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regions for backbone torsion angles psi against phi of amino acid residues in protein 
structure; the plot demonstrates the empirical distribution of data points (amino acid 
residues) observed in a single structural model. For this mOct3 model, 91.9% of amino 
acids were in the most favored region, 4.5% in the additional allowed region, and only a 
total of 3.6% in the generously and disallowed region. Also, amino acids in the 
disallowed region were located far away from the putative binding region (Figure 4.4). 
These observations imply that the structure of our model for mOct3 is plausible. 
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Table 4.1 GOLD and DOPE scores for mOct3. 
Model identifier GOLD score DOPE score 
Model 5 52.73 -47491.777 
Model 39 49.98 -47725.219 
Model 95 49.27 -46448.785 
Model 59 49.17 -47334.730 
Model 81 48.89 -47610.613 
Model 67 48.55 -47504.059 
Model 79 48.21 -48019.738 
Model 36 47.57 -47617.582 
Model 83 46.71 -47378.906 
Model 12 46.63 -47413.473 
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Figure 4.3 3-D demonstration of binding pocket for MPP+ in mouse Oct3. 
 
Residues (yellow) surrounding the binding pocket are depicted in sticks. 
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Figure 4.4 Ramachandran plot of mouse Oct3. 
 
Phi and psi indicate backbone conformation torsion angles of amino acid residues, 
which represent the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino 
acids are laid out in different regions: most favored region (red), additional allowed 
region (yellow), generously allowed region (light yellow), and disallowed region (white). 
Residues depicted in red squares are in the generously allowed and disallowed regions. 
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To determine and compare the interactions between MPP+ and mOct3 with those 
in hOCT3, MPP+ was energy minimized in SYBYL X using Tripos force field with 
Gasteiger-Hückel charges and docked to the binding pocket of the mOct3 model to 
identify amino acid residues critical for MPP+-mOct3 interactions in GOLD suite 5.4.  
From the docking result, the aromatic ring of MPP+ was located in between the 
aromatic rings of two residues, Arg20 and Phe474, in π-π stacking and edge face 
interactions (Figure 4.5). Moreover, the pyridinium ring and the benzene ring of MPP+ 
were seen to be adjacent to and interacting with Met219, Leu450, Asp473, and Ile477 in 
hydrophobic manners (Figure 4.5). Identified residues as well as their interaction types 
are summarized in Table 4.2. 
Comparing the residues directly interacting with MPP+ from both hOCT3 and 
mOct3 models, we observed that only one amino acid (Asp473) was detected in both 
models, albeit with different interaction types. We did not detect any ionic salt-bridge 
interaction resulting from residues in the binding pocket of mOct3; however, a number 
of other interactions related to the aromatic rings of MPP+ were observed (π-π stacking, 
edge face, and hydrophobic interactions). Thus, the binding pockets for MPP+ in hOCT3 
and mOct3 are not the same, but do contain some level of similarity (one common 
residue as well as similar interaction types). 
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Figure 4.5 Structure of MPP+ docked in the substrate binding region of mOct3. 
 
The ligand (MPP+, green) and ‘critical’ amino acid residues (yellow) are displayed as 
sticks. 
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Table 4.2 MPP+ docking result summary for mOct3. 
 
Amino acid residue Type of interaction 
Arg20 π-π stacking interaction 
Met219 Hydrophobic interaction 
Leu450 Hydrophobic interaction 
Asp473 Hydrophobic interaction 
Phe474 Edge face interaction 
Ile477 Hydrophobic interaction 
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4.3.2 Homology modeling of rat organic cation transporter 3 
GOLD scores of the top ten docked poses of MPP+ in the binding pocket of rOct3 
are summarized in Table 4.3 along with their corresponding DOPE scores. The largest 
GOLD score represents the best docking pose, and the smallest DOPE score 
demonstrates the best homology model. Since our focus was on the binding interaction 
between docking substrate and rOct3, our model selection criteria was primarily based 
on the GOLD score, and Models 62 and 68 had significantly higher GOLD scores 
compared to other models. Comparing the DOPE scores of these models with top 
GOLD scores, we chose Model 68 as our best 3-D homology model for rOct3 since its 
DOPE score was significantly smaller than that of Model 62. Visualizing the generated 
homology model for rOct3 in Pymol, we were able to identify all the amino acid residues 
surrounding and forming the large binding pocket for MPP+ in the transporter. The 
generated 3-D homology model along with the amino acid residues forming the MPP+ 
binding pocket are depicted as yellow sticks (Figure 4.6). These residues are from 
different transmembrane domains that intertwine and form the binding region for MPP+: 
TMD 1 (Arg16, Arg19, Arg20), TMD 2 (Asn157, Phe160), TMD 4 (Trp218, Phe222), 
TMD 5 (Gln242, Phe245), TMD 7 (Trp353, Ser356, Ala357, Tyr360, Gln361), TMD 10 
(Glu446, Val448, Tyr449), and TMD 11 (Cys472, Asp473, Gly476) (Figure 4.6). 
PROCHECK analysis of the selected rOct3 model generated its Ramachandran 
plot (Figure 4.7). Ramachandran plot provides a way to visualize energetically allowed 
regions for backbone torsion angles psi against phi of amino acid residues in protein 
structure; the plot demonstrates the empirical distribution of data points (amino acid 
residues) observed in a single structural model. For this rOct3 model, 91.9% of amino 
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acids were in the most favored region, 4.9% in the additional allowed region, and only a 
total of 3.3% in the generously and disallowed region. Also, amino acids in the 
disallowed region were located far away from the putative binding region (Figure 4.6). 
These observations imply that the structure of our model for mOct3 is plausible. 
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Table 4.3 GOLD and DOPE scores for rOct3. 
Model identifier GOLD score DOPE score 
Model 62 51.59 -47000.965 
Model 68 51.48 -47760.391 
Model 80 51.00 -47873.797 
Model 93 49.31 -47250.766 
Model 66 48.78 -47145.648 
Model 42 48.68 -47086.980 
Model 71 48.46 -47528.285 
Model 16 48.26 -47610.598 
Model 38 48.00 -47118.887 
Model 34 47.36 -47253.957 
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Figure 4.6 3-D demonstration of binding pocket for MPP+ in rat Oct3. 
 
Residues (yellow) surrounding the binding pocket are depicted in sticks. 
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Figure 4.7 Ramachandran plot of rat Oct3. 
 
Phi and psi indicate backbone conformation torsion angles of amino acid residues, 
which represent the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino 
acids are laid out in different regions: most favored region (red), additional allowed 
region (yellow), generously allowed region (light yellow), and disallowed region (white). 
Residues depicted in red squares are in the generously allowed and disallowed regions. 
 
  
!! 109!
To determine and compare the interactions between MPP+ and rOct3 with those 
in hOCT3, MPP+ was energy minimized in SYBYL X using Tripos force field with 
Gasteiger-Hückel charges and docked to the binding pocket of the rOct3 model to 
identify amino acid residues critical for MPP+-rOct3 interactions in GOLD suite 5.4.  
From the docking result, the aromatic rings of MPP+ were detected to be related 
to the aromatic rings of residues Try218, Phe245, and Tyr449 (Figure 4.8). Moreover, 
the pyridinium ring of MPP+ was observed to be interacting with the positively charged 
part of Arg20 in π-cation interaction, with Glu446 in polar-nonpolar interaction, and with 
Phe160 in a hydrophobic manner (Figure 4.8). These interactions are summarized in 
Table 4.4. 
Comparing the residues that were identified to be directly interacting with MPP+ 
from both hOCT3 and rOct3 models, we observed that only one amino acid (Glu446) 
was detected in both models, albeit with different interaction types. We did not detect 
any ionic salt-bridge interaction resulting from residues in the binding pocket of rOct3, 
however, a number of other interactions related to the aromatic rings of MPP+ were 
observed (π-π stacking, edge face, π-cation, polar-nonpolar, and hydrophobic 
interactions). An interesting observation was that the conserved aspartate residue 
(Asp473) in the hOCT3 and mOct3 models was not identified as ‘critical’ in the rOct3 
model. These results suggest that the binding pockets for MPP+ in hOCT3 and rOct3 
are not the same, but do contain some level of similarities (one common residue as well 
as similar interaction types). Taking this to the next step, we compared ‘critical’ residues 
for MPP+ interactions from the two rodent Oct3 models. Only one amino acid (Arg20) 
was detected in both models with different interaction types, and the other ‘critical’ 
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residues as well as their interaction types were dissimilar (despite one phenylalanine 
residue at different locations from both models). Thus, the binding pockets for MPP+ in 
mOct3 and rOct3 are also unique, but do contain some level of similarity. This is an 
interesting observation considering the high level of sequence similarities between 
mouse and rat Oct3. 
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Figure 4.8 Structure of MPP+ docked in the substrate binding region of rOct3. 
 
The ligand (MPP+, green) and ‘critical’ amino acid residues (yellow) are displayed as 
sticks. 
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Table 4.4 MPP+ docking result summary for rOct3. 
 
Amino acid residue Type of interaction 
Arg20 π-cation interaction 
Phe160 Hydrophobic interaction 
Try218 π-π interaction 
Phe245 Edge face interaction 
Glu446 Polar-nonpolar interaction 
Tyr449 Edge face interaction 
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4.3.3 Comparison of transporters among species 
To test the hypothesis that species differences in OCT3/Oct3 transporter affinity 
are due to sequence differences in the substrate binding pocket, ligands with 
significantly different binding affinities for OCT3 orthologs were docked to the binding 
pockets of human, mouse and rat OCT3/Oct3. 
For the comparison between hOCT3 and mOCT3, energy-minimized 
procainamide (low affinity inhibitor for hOCT3 and high affinity inhibitor for mOct3) was 
utilized, and residues involved with transporter-procainamide interactions were identified 
(Figure 4.9), along with their specific interaction types (Table 4.5). Comparing identified 
residues from both transporters, we observed two residues from hOCT3 that are 
interacting with procainamide and four residues from mOct3 responsible for 
procainamide-transporter interactions. One common residue (aspartate) was detected 
in both models, and in both scenarios this residue was interacting with a positively 
charged nitrogen atom in procainamide through an ionic salt-bridge interaction. 
Measured distances between the positively and negatively charged atoms in both 
models showed that the ionic interaction in mOct3 is stronger (shorter distance, data not 
shown). The other residue (Phe165) identified in hOCT3 was interacting with the ligand 
through an arene-H interaction, and this type of interaction was also observed in the 
mOct3 model (Val223). Two other residues in the binding pocket of mOct3 were also 
detected and acted as side-chain acceptors for procainamide. Thus, critical residues in 
mOct3 are more closely situated to the ligand and exerting stronger and more 
interactions. 
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Comparing the residues responsible for transporter-procainamide interactions 
from both hOCT3 and mOCT3 models with residues that form the binding pocket for 
MPP+ in both models, we observed that these procainamide-interacting residues are 
located in the binding pockets for MPP+, but not necessarily contributing to the 
interactions between transporters and MPP+: aspartate residues interacting with MPP+ 
were demonstrated to be interacting with procainamide as well, but the interaction type 
in mOct3 model was different from the type in hOCT3 model. This result suggests that 
OCT3-interacting compounds (inhibitor in this case) with different chemical structures 
may share the same binding region, but residues directly interacting with them are likely 
different (with some overlap). 
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Figure 4.9 Structure of procainamide docked in the substrate binding region of 
OCT3. 
 
The ligand (procainamide, green) docked in models of hOCT3 (A) and mOct3 (B), as 
well as ‘critical’ amino acid residues (yellow) are displayed as sticks. The dashed line 
indicates ionic salt-bridge interaction between the protonated amine of procainamide 
and the negatively charged residue Asp478 (Asp473 in mOct3). 
 
 
 
Table 4.5 Procainamide docking result summary for human OCT3 and mouse 
Oct3. 
 
Transporter Amino acid residue Type of interaction 
hOCT3 Phe165 Arene-H interaction 
 Asp478 Ionic salt-bridge interaction 
mOct3 Thr220 Side-chain acceptor 
 Val223 Arene-H interaction 
 Ser466 Side-chain acceptor 
 Asp473 Ionic salt-bridge interaction 
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For the comparison between hOCT3 and rOCT3, energy-minimized 
norepinephrine (low affinity substrate for hOCT3 and high affinity inhibitor for rOct3) was 
utilized, and residues involved with ligand-transporter interactions were identified 
(Figure 4.10), along with their specific interaction types (Table 4.6). Comparing 
identified residues from both transporters, we observed three residues from hOCT3 that 
are interacting with norepinephrine and six residues from rOct3 responsible for 
norepinephrine-transporter interactions. The same common residue (aspartate) was 
again detected in both models, and in both scenarios, this residue was acting as a side-
chain acceptor towards the docked compound. The other residues identified in hOCT3 
were interacting with norepinephrine through arene-H interaction and as a side-chain 
acceptor. Five other residues in the binding pocket of rOct3 were also detected and 
acted either as side-chain donors for norepinephrine or interacted with the compound 
due to aromatic rings. Thus, there are more critical residues in rOct3 interacting with 
norepinephrine, and the types of interactions (for example π-π interaction) are stronger 
compared to that of the hOCT3 model. 
Comparing the residues responsible for transporter-norepinephrine interactions 
from both hOCT3 and rOCT3 models with residues that form the binding pocket for 
MPP+ in both models, we observed that these norepinephrine-interacting residues are 
located in the binding pockets for MPP+, but not necessarily contributing to the 
interactions between transporters and MPP+. The aspartate residue interacting with 
MPP+ was demonstrated to be interacting with norepinephrine as well, but the 
interaction type in rOct3 model was different from the type in hOCT3 model. The 
phenylalanine residue (Phe36) was demonstrated to be interacting with both MPP+ and 
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norepinephrine in hOCT3 through different types of interactions. Arg20 (with different 
interaction types) and Trp218 (with the same type of interaction) were demonstrated to 
be interacting with both MPP+ and norepinephrine in rOct3. These results further 
suggest that OCT3-interacting compounds with different chemical structures may share 
the same binding region, but residues directly interacting with them are likely different 
(with some overlap). 
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Figure 4.10 Structure of norepinephrine docked in the substrate binding region of 
OCT3. 
 
The ligand (norepinephrine, green) docked in models of hOCT3 (A) and rOct3 (B), as 
well as ‘critical’ amino acid residues (yellow) are displayed as sticks. 
 
Table 4.6 Norepinephrine docking result summary for human OCT3 and rat Oct3. 
 
Transporter Amino acid residue Type of interaction 
hOCT3 Phe36 Arene-H interaction 
 Met248 Side-chain acceptor 
 Asp478 Side-chain acceptor 
rOct3 Arg19 Side-chain donor 
 Arg20 Side-chain donor 
 Phe160 Edge face interaction 
 Lys215 Side-chain donor 
 Trp218 π-π interaction 
 Asp473 Side-chain acceptor 
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4.4 Discussion 
 Organic cation transporter 3 is the most widely expressed isoform among the 
OCTs [1]. Regardless of species, the transporter is responsible for absorption, 
distribution, and elimination of small organic cations in a variety of tissues including 
intestine, liver, heart, brain, and so on [1]. Even though the OCT3 orthologs share a 
great deal of similarity, interactions with compounds do exhibit some inter-species 
differences. As we tried to use information gathered from conducting homology 
modeling and docking to understand possible transporter-substrate interactions of 
hOCT3 (Chapter 3), using a similar method to conduct homology modeling and docking 
on mouse and rat Oct3 and comparing results from these three species could help us 
understand possible reasons for inter-species differences. 
 In this study, we successfully generated homology models for mouse and rat 
Oct3 using the inorganic phosphate transporter PiPT as template; Ramachandran plots 
for the two transporters indicate the models are in acceptable conformations (with more 
than 90% of residues located in favorable regions, Figure 4.4 and Figure 4.7). Binding 
pockets of mouse and rat Oct3 were defined along with residues that form the pockets 
(Figure 4.3 and Figure 4.6). Comparing these amino acid residues, we observed that 
there are great differences between the binding pockets of both transporters, i.e. most 
amino acids forming the binding pockets in mOct3 and rOct3 are different (Figure 4.3 
and Figure 4.6). The discrepancy between mouse and rat Oct3 could also be observed 
in residues involved with MPP+-transporter interactions (Table 4.1 and Table 4.2), only 
one amino acid (Glu446) was detected in both models. The binding pocket of human 
OCT3 is also different from pockets of rodent orthologs, however, analyzing amino acid 
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residues identified to form the binding pockets has shown that the transmembrane 
domains where these residues originated from are the same regardless of species 
(TMDs 1, 2, 4, 5, 7, 10, and 11), thus revealing structural similarities among species. 
 Despite similar transport profiles for most substrates/inhibitors, transport affinities 
of several compounds are vastly divergent for different OCT3 orthologs [26, 27, 70, 73]. 
This is the first study using 3-D homology models to analyze inter-species differences of 
OCTs. In order to study this inter-species transport difference, 3-D homology models of 
transporters were docked with substrates that have distinct affinities for OCT3 
orthologs. Since no compound with significantly different affinities for all three OCT3 
orthologs has been identified, we first compared hOCT3 and mOCT3 using 
procainamide (an inhibitor for both transporters) [27, 73]. After docking procainamide to 
the binding region of hOCT3/mOct3, amino acid residues that could be of importance in 
interactions between the inhibitor and transporter were proposed and they all belonged 
to the pre-defined MPP+ binding pocket (Table 4.5). An aspartate residue was identified 
to interact with procainamide through ionic salt-bridge interaction in both models, while 
the ionic interaction in mOct3 is stronger than that in hOCT3. Comparing the specific 
types of interactions between other ‘critical’ residues (Phe165 in hOCT3; Thr220, 
Val223, and Ser466 in mOct3) and procainamide, we observed that critical residues in 
mOct3 are more closely situated to the ligand and implement stronger interactions, 
which could be the reason why the affinity for procainamide in mouse Oct3 (IC50=11 
µM) is significantly higher (~ 70 times stronger) than that in human OCT3 (IC50=738 µM) 
[27, 73]. 
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Study of the inter-species transport differences between hOCT3 and rOCT3 was 
also performed using norepinephrine (substrate for hOCT3 and inhibitor for rOct3). 
Critical residues interacting with norepinephrine were identified through docking of 
norepinephrine to the binding region of hOCT3/rOct3 (summarized in Table 4.6). These 
residues all belonged to the pre-defined MPP+ binding pocket in both models. The same 
aspartate residue was identified to interact with norepinephrine as side-chain acceptors 
in both models. Comparing the specific types of interactions between other ‘critical’ 
residues (Phe36 and Met248 in hOCT3; Arg19, Arg20, Phe160, Lys215, and Trp218 in 
rOct3) and norepinephrine, we observed that there are more critical residues in rOct3 
interacting with the ligand and the interactions are stronger compared to those in 
hOCT3 (aromatic interactions in rOct3 versus hydrogen bonds in hOCT3), which could 
be the reason why the affinity for norepinephrine in rOct3 (IC50=432 µM) is significantly 
higher (~ 6 times stronger) than that in hOCT3 (Km=2630 µM) [26, 70]. 
In summary, as the first study analyzing inter-species differences among OCT3 
orthologs, we successfully generated 3-D homology models for mouse and rat organic 
cation transporter 3, identified their binding pockets for MPP+, amino acid residues 
forming the binding pockets, as well as residues that are critical for interactions between 
transporter and MPP+. Through more docking studies with procainamide and 
norepinephrine, residues critical for ligand-transporter interactions were identified. We 
concluded that the binding pockets of OCTs could be different despite the high 
sequence similarity between transporters (mouse and rat Oct3). Docking of the two 
compounds suggested that ligands bind to different regions inside the large binding 
pocket of OCT3. Differences in the strength and number of strong binding interactions 
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between ligand and transporter are contributing to the inter-species differences in 
binding affinities. 
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Chapter 5 
KINETIC INVESTIGATION OF THE INTERACTION BETWEEN A NOVEL SERIES OF 
COMPOUNDS EXHIBITING ANTI-DEPRESSANT LIKE EFFECTS AND ORGANIC 
CATION TRANSPORTERS 
 
 
5.1 Introduction 
Depressive disorder, also known as depression, is one of the most burdensome 
psychiatric disorders in the world. It is often accompanied by low self-esteem, loss of 
interest in normally enjoyable activities, low energy, and pain without a clear cause [99]. 
Depressive disorder can negatively affect a person’s personal, work, or school life, as 
well as sleeping, eating habits, and general health [106]. Approximately 6-7% of full-
time U.S. workers experienced depressive disorder within the year 2015, the total 
economic burden of the disease is estimated to be $210.5 billion per year, and for every 
dollar spent on depression direct costs in 2010, an additional $1.9 was spent on 
depression-related indirect costs [107]. Between 2-7% of adults with depression die by 
suicide, and up to 60% of people who die by suicide had depressive disorder or other 
mood disorders [108]. Although plenty of antidepressant drugs have been used to treat 
the disease, side effects and delayed onset of action are often observed in clinical 
applications [76]. And these treatments fail to produce beneficial effects in nearly half of 
the patients [75]. 
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The cause of depressive disorder is believed to be a combination of genetic, 
environmental, and psychological factors [99]. Previous studies have demonstrated that 
depression is often associated with a reduction of monoamine neurotransmitters such 
as 5-HT and NE in the synaptic clefts [35, 109]. Therefore, understanding the 
mechanism of 5-HT clearance in the brain is vital for developing antidepressant drugs. 
There are two distinguishable mechanisms of aminergic neurotransmitter clearance 
from the synaptic cleft: uptake-1 system (high-affinity, low capacity reuptake through 
SERT, NET, and DAT) and uptake-2 system (low-affinity, high capacity reuptake) [100]. 
Currently, most antidepressants are thought to work by blocking the uptake-1 system 
[75]. Alternatively, the uptake-2 system has gradually gained attention as a new 
therapeutic target for antidepressants. Increasing evidence has indicated that organic 
cation transporter 2 (OCT2) and 3 (OCT3), which are widely expressed in the CNS, 
interact with different kinds of neurotransmitters (DA, 5-HT, and NE) and likely represent 
important components of the uptake-2 system [35]. For example, administering the OCT 
inhibitor, normetanephrine, in mice increased extracellular NE levels in brain and 
produced enhanced antidepressant-like effects [110]. Furthermore, the expression and 
function of Oct3 in the CNS was significantly increased in SERT knockout mice [30, 78]. 
Therefore, OCTs may represent unrecognized targets of antidepressants and may 
impact their pharmacological actions. 
Recently, a series of compounds has been synthesized as potential novel 
therapeutic agents for treating depression in the laboratory of Dr. Malgorata Dukat 
(Department of Medicinal Chemistry, VCU). Analysis of lead compounds (closely related 
to test compounds in this study) have shown promising antidepressant-like effects in 
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mice (Dr. Dukat laboratory, unpublished data). Studies of these compounds suggested 
that they might not be potent inhibitors of the uptake-1 system, considering their binding 
affinities for SERT and NET were greater than 10 µM (Dr. Dukat laboratory, unpublished 
data). Looking at the logP values, molecular weights, and chemical structures (not 
shown here) of these test compounds, it was determined that they might be OCT 
substrates and/or inhibitors, potentially exhibiting antidepressant-like effects via uptake-
2 inhibition. To test this hypothesis, we examined the interactions of test compounds 
with hOCT1-3 and mOct1-3 to determine if OCTs could play a role in their 
antidepressant-like action. 
 
5.2 Materials and Methods 
5.2.1 Chemicals 
Tritiated 1-methyl-4-phenylpyridinium ([3H]MPP+) was purchased from 
PerkinElmer Life and Analytical Science (Waltham, MA), and unlabeled MPP+ was 
obtained from Sigma-Aldrich (St. Louis, MO). Quinine monohydrochloride dihydrate was 
purchased from Acros Organics (Fair Lawn, NJ). The test compounds were synthesized 
and provided by Dr. Dukat’s laboratory. Details of structures and synthetic routes are 
not provided at this time (proprietary information). 
5.2.2 Tissue Culture 
Stably transfected human embryonic kidney 293 (HEK) cells expressing hOCT1 
(HEK-hOCT1), hOCT2 (HEK-hOCT2), hOCT3 (HEK-hOCT3), mOct1 (HEK-mOct1), 
mOct2 (HEK-mOct2), or mOct3 (HEK-mOct3), and their empty vector transfected 
background control cell lines were maintained at 37°C with 5% CO2 in DMEM high 
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glucose medium (Mediatech Inc., Herndon, VA) containing 10% FBS, 1% 
penicillin/streptomycin, as well as 600 µg/ml G418. 
 
5.2.3 Cellular Uptake Assay 
The procedure for cell accumulation assay has been described previously with 
minor modification [94].Two days before cellular uptake experiment, 2*105 cells/well 
were seeded in 24-well tissue culture plates (coated with poly-D-lysine) and grown in 
the absence of antibiotics. On the day of experiment, cells were equilibrated in transport 
buffer at room temperature (22-25°C) for 10 min. After equilibrium, this solution was 
replaced with 500 µL of fresh transport buffer containing unlabeled MPP+ (1 µM) spiked 
with [3H]MPP+ (0.25 µCi/mL) in the presence of increasing concentrations (0.1 to 200 
µM) of unlabeled test compounds for the times indicated. At the end of the incubation, 
the cells were quickly rinsed three times with ice-cold transport buffer and lysed with 
200 µL NaOH (1 N). After shaking for two hours, mixture was neutralized with 250 µL 
HCl (1 N) and 200 µL HEPES (0.01 M). The radioactivity of cell lysate (400 µL from 
each well) was quantified by liquid scintillation counting, and the uptake profile was 
normalized by the total protein content (quantified using the Bradford method). The 
cellular uptake of substrates was shown as picomoles of substrate per milligram total 
protein. Substrate concentration and accumulation time used for kinetic analysis of 
hOCT1, hOCT2, hOCT3, mOct1, mOct2 and mOct3 (1 µM for MPP+ 1 min) were 
determined previously [3, 25]. All uptake data were corrected for background 
accumulation in corresponding empty vector transfected control cells. Kinetic 
calculations were performed using GraphPad Prism Software version 5.0 (GraphPad 
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Software Inc., San Diego, CA). The half maximal inhibitory concentration (IC50) was 
calculated using nonlinear regression and the “log(inhibitor) vs. response” model. 
Results were confirmed by repeating all experiments at least three times with triplicate 
wells for each data point in every experiment. 
5.2.4 Statistics 
Data are reported as mean ± SD. Statistical differences were analyzed using one-way 
ANOVA followed by Dunnett’s post-hoc t-test (α=0.05). 
 
5.3 Results 
5.3.1 Initial screening of test compounds as OCT inhibitors 
 The inhibitory effects of test compounds were initially screened on three human 
OCTs and three mouse Octs using MPP+ as prototypical substrate. Stably transfected 
hOCT1-expressing (HEK-hOCT1) cells showed marked accumulation of MPP+ (~62 
fold) compared to empty vector transfected background control cells (124.2 ± 1.3 vs. 2.0 
± 0.2 pmol/mg protein/10 min, respectively; data not shown). HEK-mOct1 cells exhibited 
~44 fold accumulation of MPP+ as compared to empty vector transfected background 
control cells (88.8 pmol/mg protein/10 min). The known OCT inhibitor, quinine (200 µM), 
showed virtually complete inhibition of hOCT1- and mOct1-mediated MPP+ uptake (> 
90% inhibition; Figure 5.1 (A) and (B)). The cell accumulation assay demonstrated that 
all test compounds (100 µM) significantly inhibited hOCT1 activity (Figure 5.1 (A)). In 
HEK-mOct1 cell experiments, all test compounds (100 µM) except KAI419 significantly 
inhibited MPP+ transport by mOct1 (Figure 5.1 (B)). 
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The inhibitory effects of test compounds on hOCT2- and mOct2-mediated 
transport were examined next. Stably transfected hOCT2-expressing (HEK-hOCT2) 
cells showed significantly higher amount of accumulation of MPP+ (~58 fold) compared 
to empty vector transfected background control cells (115.4 ± 0.1 pmol/mg protein/10 
min). HEK-mOct2 cells exhibited ~48 fold accumulation of MPP+ as compared to empty 
vector transfected background control cells (95.8 pmol/mg protein/10 min). The known 
OCT inhibitor, quinine (200 µM), showed almost complete inhibition of hOCT2- and 
mOct2-mediated MPP+ uptake (> 98% inhibition; Figure 5.1 (C) and (D)). The cell 
accumulation assay demonstrated that all test compounds significantly inhibited hOCT2 
and mOct2 activity at the concentration of 100 µM (Figure 5.1 (C) and (D)). 
Stably transfected hOCT3-expressing (HEK-hOCT3) cells showed significant 
accumulation of MPP+ ~56 fold greater than empty vector transfected background 
control cells (111.2 pmol/mg protein/10 min), and mOCT3 transfected HEK cells 
showed ~10 fold greater accumulation of MPP+ compared to control cells with value of 
99.2 pmol/mg protein/10 min. MPP+ transport was almost completely (> 90% inhibition; 
Figure 5.1 (E) and (F)) blocked by quinine (200 µM), a prototypical inhibitor for OCTs. 
All test compounds at a concentration of 100 µM significantly inhibited MPP+ uptake by 
hOCT3 and mOct3 (Figure 5.1 (E) and (F)). 
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Figure 5.1 Inhibition profiles of test compounds on OCTs. 
 
Inhibition of (A) hOCT1-, (B) mOct1-, (C) hOCT2-, (D) mOct2-, (E) hOCT3-, and (F) 
mOct3-mediated MPP+ uptake by test compounds (blue, 100 uM) and quinine (black, 
200 uM). The concentration of MPP+ was 1 uM, incubation time was 10 min, and data 
shown were corrected for non-specific background. Values are mean ± SD of triplicate 
values. * denotes p < 0.05 as determined by one-way ANOVA followed by Dunnett’s t-
test.  
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5.3.2 Determination of IC50 values for test compounds 
 Based on the initial screening results, IC50 values of KAI394 for mOct2, of 
KAI419 for mOct1, mOct2, and mOct3, and of MDK018 for all OCT isoforms were not 
determined because they did not produce more than 50% inhibition of MPP+ transport, 
indicating their IC50 values would be larger than 100 µM (Figure 5.1). From the 
screening result, it was seen that MDK018 is not a potent inhibitor for organic cation 
transporters.  
Dose-response studies were conducted to estimate the IC50 values of test 
compounds exhibiting ≥ 50% inhibition on hOCT1, hOCT2, hOCT3 and their murine 
orthologs. IC50 values of test compounds for hOCT1 were in the low micro-molar range 
(2.6 µM to 6.3 µM) except for KAI419 (Figure 5.2, Table 5.1). The IC50 value of KAI419 
for hOCT1 was estimated as 23.3 ± 0.9 µM, which is 4-9 fold higher than the other 
compounds (Figure 5.2, Table 5.1). Compared with hOCT1 results, IC50 values of test 
compounds for mOct1 were considerably higher (18.6 µM to 37.2 µM), and KAI419 did 
not inhibit more than 50% of MPP+ transport in the screening study (Figure 5.3, Table 
5.1). Thus, the test compounds exhibited stronger inhibition of hOCT1 than mOct1, 
indicating a species difference. The IC50 values for the two transporters have a similar 
trend with KAI419 being the least effective test compound. 
IC50 values of test compounds for hOCT2 were also higher compared to those for 
hOCT1 (5.1 µM to 48.0 µM). Test compounds exhibit their inhibitory effects towards 
hOCT1 and 2 in a similar trend, with KAI414 being the most potent inhibitor (5.1 ± 1.3 
µM) and KAI419 being the worst inhibitor (48.0 ± 18.7 µM) (Figure 5.4, Table 5.1). The 
IC50 values of test compounds for mOct2 ranged from 4.0 µM to 22.4 µM, and the 
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values of KAI394 and KAI419 were higher than 100 µM (IC50 not determined) (Figure 
5.5, Table 5.1). Thus, unlike for the OCT1 orthologs, the inhibition profiles for OCT2 in 
two species are very similar. KAI414 was also the most potent inhibitor of mOct2 (4.0 ± 
0.9 µM). 
Dose-response studies for hOCT3 and mOct3 indicated that the IC50 values of 
test compounds for hOCT3 were also in the low micro-molar range (1.4 µM to 8.4 µM) 
except for KAI419 (Figure 5.6, Table 5.1). The IC50 value of KAI419 for hOCT3 was 
determined as 26.9 ± 8.5 µM, which is 3 – 19 fold higher than the other compounds 
(Figure 5.6, Table 5.1). This situation is extremely similar to the case in hOCT1. 
Compared with hOCT3 results, IC50 values of test compounds for mOct3 were also 
considerably higher (17.4 µM to 40.9 µM), and KAI419 could not inhibit more than 50% 
of MPP+ transport in the screening study (Figure 5.7, Table 5.1). Therefore, the test 
compounds more efficiently inhibited hOCT3 than mOct3, indicating a species 
difference, similar to he trend in hOCT1/mOct1 inhibition. One outstanding point was 
that KAI422 did not inhibit more than 50% MPP+ uptake on mOct3, in contrast to being 
rather potent for the other five OCTs. 
All test compounds showed potent affinities for human OCT1 and OCT3, and 
among the other transporters, mOct2 seemed to have the highest affinity towards the 
compounds (Table 5.1). Besides MDK018, which showed minimum inhibition effect for 
all transporters, KAI419 was the least potent inhibitor across all OCT subtypes. 
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Figure 5.2 Dose-response curves for test compounds on hOCT1. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT1 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-4 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 5.3 Dose-response curves for test compounds on mOct1. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct1 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-3 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 5.4 Dose-response curves for test compounds on hOCT2. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT2 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-3 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 5.5 Dose-response curves for test compounds on mOct2. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct2 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-3 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 5.6 Dose-response curves for test compounds on hOCT3. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT3 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-3 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 5.7 Dose-response curves for test compounds on mOct3. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct3 
cells in the presence of increasing concentrations of test compounds (10-7 to 10-3 M) are 
shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Table 5.1 IC50 values of test compounds for human and mouse OCTs 
 
Compound 
IC50a (µM) 
hOCT1 hOCT2 hOCT3 mOct1 mOct2 mOct3 
KAI382 6.3 ± 1.3 12.8 ± 0.7 8.4 ± 4.4 18.6 ± 7.6 8.9 ± 2.5 23.3 ± 9.6 
KAI389 5.6 ± 0.4 36.5 ± 9.1 2.0 ± 0.2 37.2 ± 14.2 22.4 ± 5.9 19.6 ± 3.4 
KAI394 4.3 ± 1.6 35.7 ± 0.2 3.8 ± 0.4 38.0 ± 4.9 NDb 40.9 ± 18.2 
KAI404 2.7 ± 1.0 10.1 ± 0.3 2.2 ± 0.3 33.5 ± 6.3 13.8 ± 3.4 17.4 ± 3.3 
KAI414 2.6 ± 0.5 5.1 ± 1.3 1.4 ± 0.1 19.2 ± 3.8 4.0 ± 0.9 18.6 ± 4.4 
KAI419 23.3 ± 0.9 48.0 ± 18.7 26.9 ± 8.5 ND ND ND 
KAI422 5.7 ± 0.8 11.7 ± 3.2 5.0 ± 0.6 22.6 ± 2.3 8.6 ± 5.2 ND 
MDK018 ND ND ND ND ND ND 
 
aIC50 values were expressed as mean ± SD from triplicate determinations. 
bND, not determined. 
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5.4 Discussion 
Depressive disorder is the fourth leading cause of illness-induced disability 
according to the global burden of disease study in 2010, and it is predicted to reach the 
second place by 2020 [111]. Although a wide variety of drugs have been developed and 
used in treating depression clinically, approximately half of the treated patients failed to 
find relief using current therapies, especially in mild or moderate cases of depression 
[109, 112]. This may be due to the presence of multiple clearance pathways for 
monoamine neurotransmitters in the brain subject to different modes of regulation. 
Undesirable side effects, including nausea, weight change, anxiety, sexual dysfunction, 
increased bone fracture risk and gastrointestinal effects, are often observed in the 
clinical application of antidepressants [36, 75]. Both side effects and the lack of 
response to traditional therapeutics indicate an unmet need to develop antidepressants 
with novel mechanisms of action, which will ideally bring greater efficacy as well as 
fewer side effects compared to existing antidepressants. Recently, human OCT2 and 
OCT3 have been discovered as key components of uptake-2 system and suggested to 
play an important role in regulating neurotransmitter clearance in human brain [26, 34]. 
A number of currently used antidepressants, such as fluoxetine, desipramine, and 
sertraline, are proven to be effective OCT inhibitors in vitro [98, 104]. Currently, it 
remains unclear what role OCTs have in the therapeutic action of these compounds; 
however, together the evidence suggests OCTs may be viable targets in treating mood 
disorders. 
The test compounds examined in this study are a series of novel compounds 
developed as potential therapeutic agents for treating depression [105, 113]. Previous 
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kinetic studies on other compounds in the same class with similar structures (also 
generated from Dr. Dukat’s laboratory) yielded high binding affinities for SERT and NET 
(greater than 10 µM); however, a chloride substituted compound demonstrated potent 
antidepressant-like effects in mice, indicating the possibility of another working 
mechanism (maybe through targeting uptake-2 system) [105]. In the present study, the 
interactions of eight novel compounds with OCTs were studied. The inhibitory effects of 
the compounds varied among different orthologs and paralogs of OCT3, and also 
depended on their structures (structures not shown at this point). Overall, mOct1 was 
least sensitive towards compound inhibition, and hOCT2 is the least sensitive in human 
OCT paralogs (Table 5.1). Several test compound(s) (e.g., KAI422) showed significantly 
different inhibitory affinities across human and mouse transporters, and could potentially 
be used as a method to differentiate corresponding transporters. In general, murine 
orthologs were less sensitive to inhibition by test compounds as compared to human 
orthologs (Table 5.1). The IC50 values of test compounds for mOct2 were comparable 
(0.6 to 1.4 fold) to those of hOCT2, whereas relatively weaker inhibitory effects were 
observed for mOct1 and mOct3 compared to those of their human orthologs. Of the 
eight test compounds, MDK018 did not demonstrate significant inhibitory effects for any 
tested transporter, and KAI414 was the most potent compound for the transporters 
(except for slightly higher IC50 value in mOct1). 
In summary, eight compounds were examined and potent inhibitors for 
hOCTs/mOcts were identified. The inhibitory effects of compounds with hOCTs/mOcts 
were tested and compared. Results suggest that novel lead compounds, such as 
KAI414, could be further tested in mice to look for antidepressant-like effects, and 
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docking of these compounds to homology models of OCTs should provide useful 
knowledge regarding highly interactive functional groups. This structure-activity 
relationship information combined with in vivo (previous study by Dr. Dukat’s laboratory) 
and in vitro data could support and help with designing the next generation of 
antidepressants. 
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Chapter 6 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Organic cation transporters are typically located on the membrane of polarized 
barrier epithelia and are responsible for the absorption, distribution, and elimination of 
small organic cations including metabolites and drugs [1]. The wide expression of OCT3 
in various peripheral organs such as heart, skeletal muscle, brain, small intestine, liver, 
lung, kidney, and its broad substrate selectivity make the transporter a target for 
therapeutics as well as a good candidate for rational drug design, but also could result 
in undesirable side effects (including drug-drug interactions) [1]. Decades have passed 
since the OCTs have been cloned, but little is known about their transport mechanism, 
except that they are driven by electrochemical gradient [114]. Thus elucidating the 
molecular mechanism of OCT3-substrate interactions is important for understanding 
substrate/inhibitor recognition, drug-drug interaction, and for rational drug design. In this 
study, we began to study the structure as well as substrate/inhibitor interactions of 
hOCT3 and its rodent orthologs through homology modeling, and also the potential role 
of OCT inhibitors in major depressive disorders. 
Since no crystal structure of the SLC22 family has been generated, conducting 3-
D homology modeling is the only method to get a close estimation of the structure of the 
transporters. Even though a number of studies have been conducted to learn about 
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OCT transport mechanism (specifically transporter-substrate interactions), the lack of a 
high quality template with acceptable sequence identity has made these models 
obsolete, and could not be used to guide mutational studies (only models with more 
than 25% similarity compared to the template could be properly used) [49]. In chapter 3 
and chapter 4, we created homology models for human, mouse, and rat OCT3 to study 
their substrate-binding interactions as well as inter-species differences in OCT3-
compound interactions. PiPT, the crystal structure of which has recently been 
established, is an inorganic phosphate transporter that shares high structure and 
sequence similarities to the transporters of the SLC22 family, and was chosen as the 
template for model construction [92]. In chapter 3, we used in silico modeling to study 
binding interactions between hOCT3 and different substrates. A 3-D homology model of 
hOCT3 was generated based on multiple model validation methods, and a pocket 
region for substrate/inhibitor binding interactions was identified. In the docking study 
with MPP+, a prototypical substrate for OCT, five key amino acid residues were 
identified that interact with the ligand, namely Phe36, Val40, Trp358, Asp451, and 
Glu478.  The validity for this hypothesized binding profile was verified through in vitro 
MPP+ transport assays on cell lines transfected with hOCT3 mutated at these sites. 
MPP+ transport activity of hOCT3 was altered after residue substitutions, with complete 
loss of MPP+ transport in Val40, Trp358 and Glu478 mutants, as well as significant 
decrease of transporter-MPP+ affinity in the other mutants (except Phe36Tyr and 
Glu451Asp). Three-dimensional homology model for a hOCT3 mutant with decreased 
MPP+ transport activity (Val40Leu) was generated and the binding pocket was not 
drastically changed; substituted residue was located farther away from the ligand while 
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other critical residues were still interacting with MPP+, however the interactions were 
weaker. Models for hOCT3 mutants with no MPP+ transport activity were also 
generated; docking with MPP+ showed only weak interactions between the ligand and 
binding pocket residues in each model, and the binding pockets were changed to a 
large extent. Docking studies with structurally divergent hOCT3 substrates, serotonin, 
metformin, TPA+, and epinephrine, demonstrated binding interactions between ligands 
and critical residues. Comparing key residues for different substrates, we observed that 
some of the amino acid residues only worked in the interaction with one type of 
substrate, while other residues were identified more than once, thus interacting with 
different substrates. These residues include Phe36, Val40, Asn162, Met248, Trp358, 
and Asp478. These results suggest that different substrates bind to the same binding 
pocket of hOCT3, but the specific location/region where a ligand binds could be different 
and may overlap. Comparison between our binding pocket of hOCT3 and identified 
residues in literature has suggested that binding pockets of OCTs are different in 
different paralogs, but they do share certain level of similarity. 
Human OCT3 and its rodent orthologs share a great extent of sequence, 
structural, and functional similarities [1]. However, the transport profile for a few 
substrates and inhibitors are largely divergent among species [1]. For instance, 
procainamide, a drug for treating cardiac arrhythmias, is a low affinity inhibitor for 
hOCT3 (IC50 = 738 µM), but a high affinity inhibitor for mOct3 (IC50 = 11 µM); 
norepinephrine, a monoamine neurotransmitter, is a low affinity inhibitor for hOCT3 (IC50 
= 2630 µM), but a substrate for mOct3 with higher affinity (Km = 432 µM) [26, 27, 70, 
73]. In chapter 4, we assessed possible reasons for inter-species differences among 
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human, mouse, and rat OCT3 through in silico modeling and docking studies. Three-
dimensional homology models for mouse and rat Oct3 were created using the same 
protocol as for hOCT3, and binding regions were determined. Binding pockets of 
human, mouse, and rat OCT3 were all formed by amino acid residues from the same 
transmembrane domains (TMDs 1, 2, 4, 5, 7, 10, and 11), regardless of species. 
Binding pockets for human, mouse, and rat OCT3 are different from each other, even 
though mouse and rat Oct3 share high sequence identity. In the docking study with 
procainamide, a strong ionic salt-bridge interaction between one key residue (Asp) in 
OCT3 and the inhibitor was observed for both models (distance between ligand and 
residue was closer in mOct3). The types of interactions as well as distances to the 
ligand from other ‘critical’ residues (Phe165 in hOCT3; Thr220, Val223, and Ser466 in 
mOct3) have demonstrated that the amino acid residues in mOct3 are more closely 
situated to the ligand and implement stronger interactions, which could lead to the 
higher affinity for procainamide in mOct3. In the docking study with norepinephrine, the 
same aspartate residue was identified to interact with norepinephrine as side-chain 
acceptors in both hOCT3 and rOct3 models. The types of interactions of other ‘critical’ 
residues (Phe36 and Met248 in hOCT3; Arg19, Arg20, Phe160, Lys215, and Trp218 in 
rOct3) interacting with norepinephrine have demonstrated that there are more critical 
residues in rOct3 interacting with the ligand and the interactions are stronger compared 
to those in hOCT3 (aromatic interactions in rOct3 versus hydrogen bonds in hOCT3), 
which could be the reason for the higher affinity for norepinephrine on rOct3. Therefore, 
differences in transporter substrate/inhibitor affinity profiles among OCT3 orthologs may 
be explained by differing strength of interactions between ligands and transporters. 
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The novel test compounds examined in this work represent a series of 
compounds developed as potential therapeutics that possess antidepressant-like 
effects. However, previous studies of compounds of the same family failed to 
significantly inhibit uptake-1 activity (Dr. Dukat laboratory, unpublished data). Based on 
their physiochemical properties, we hypothesized that these compounds may be OCT 
inhibitors and act on uptake-2 system, which may explain the possible antidepressant-
like effects. In Chapter 5, we assessed the inhibitory effects of eight test compounds on 
three OCTs in both human and mouse. At 100 µM, all test compounds except for 
MDK018 showed significant inhibition on three human OCTs. The IC50 values for six of 
these test compounds (KAI382, KAI389, KAI394, KAI404, KAI414, and KAI422) were in 
the low micro-molar range on hOCT1 and hOCT3 (1.4 ~ 8.4 µM), and were higher for 
hOCT2. This trend was not observed in mOcts; IC50 values for test compounds on 
mOct2 were smaller than mOct1 and mOct3. MDK018 and KAI419 had the worst 
inhibitory effects on OCTs, while KAI414 had the highest inhibitory effect on OCTs. 
Most inhibition was observed in hOCT1 and hOCT3, and since hOCT1 is not as highly 
expressed in the brain compared with hOCT2 and hOCT3, administering these test 
compounds in vivo might work favorably towards inhibition of hOCT3. The present study 
suggests that novel OCT inhibitors might have the potential to produce antidepressant-
like effects through inhibiting the uptake-2 system, and test compounds with high 
affinities towards OCTs could be used as lead compounds for conducting further in vivo 
studies. 
In Chapters 3 and 4, we generated homology models for human, mouse, and rat 
OCT3, as well as for hOCT3 mutants, to evaluate and study ligand-transporter 
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interactions in their binding pockets. In order to rule out the possibility that loss of 
transport activity was due to lack of transporter expression in the plasma membrane, 
experiments using hOCT3 and FLAG antibodies to perform western blot analysis and/or 
immunocytochemistry on functional and non-functional hOCT3 mutant transfected cell 
lines are ongoing. For future studies, docked hOCT3 substrates other than MPP+ should 
be used to perform saturation assays in order to verify the importance of residues 
identified in docking studies. In addition, besides comparing homology models among 
orthologs, OCT paralogs should also be considered. This could be done by generating 
homology models for hOCT1 and hOCT2. Analyzing their binding pockets could help us 
understand their functional differences. Even though no residue subject to non-
synonymous SNP as been identified to form the binding pocket for hOCT3, one of the 
naturally occurring SNPs, Gly475Ser, is located next to the binding pocket. A 3-D 
homology model of this mutant could be generated and used to analyze the potential 
changes in its binding pocket and transport function, which might be associated with 
alterations in compound disposition observed in vivo. Another major reason for 
conducting homology modeling is to better understand compound-transporter 
interactions and generate a pharmacophore for a series of compounds in order to guide 
future rational drug design or screening for potential substrates/inhibitors, and even to 
use this information to avoid drug-drug interactions. 
In Chapter 5, we assessed the inhibitory effects of a series of test compounds on 
both human and mouse OCTs. Compounds with high affinities towards OCTs should be 
used as lead compounds and tested in vivo to evaluate their antidepressant-like effects 
through methods such as tail suspension test. Since major depressive disorder is 
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associated with decreased levels of neurotransmitters (especially 5-HT) in the CNS, 5-
HT should be used as substrate instead of MPP+ in saturation analyses, and inhibitory 
effects of these compounds on 5-HT transport through OCTs should be tested. These 
compounds should also be docked into homology models for interaction analyses. 
Incorporating the docking results, the chemical structures of test compounds and their 
binding affinities (IC50 values), we could extrapolate critical functional groups or 
pharmacophore that would facilitate inhibitory effects of the compounds, and this could 
be a start for rational drug design. 
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